<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJO</journal-id>
<journal-title-group>
<journal-title>International Journal of Oncology</journal-title></journal-title-group>
<issn pub-type="ppub">1019-6439</issn>
<issn pub-type="epub">1791-2423</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ijo.2015.3007</article-id>
<article-id pub-id-type="publisher-id">ijo-47-01-0025</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Interactional role of microRNAs and bHLH-PAS proteins in cancer (Review)</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>YUMIN</given-names></name><xref rid="af1-ijo-47-01-0025" ref-type="aff">1</xref><xref rid="af2-ijo-47-01-0025" ref-type="aff">2</xref><xref rid="fn1-ijo-47-01-0025" ref-type="author-notes">*</xref><xref ref-type="corresp" rid="c1-ijo-47-01-0025"/></contrib>
<contrib contrib-type="author">
<name><surname>WEI</surname><given-names>YUCAI</given-names></name><xref rid="af1-ijo-47-01-0025" ref-type="aff">1</xref><xref rid="af2-ijo-47-01-0025" ref-type="aff">2</xref><xref rid="fn1-ijo-47-01-0025" ref-type="author-notes">*</xref></contrib>
<contrib contrib-type="author">
<name><surname>GUO</surname><given-names>JIWU</given-names></name><xref rid="af1-ijo-47-01-0025" ref-type="aff">1</xref><xref rid="af2-ijo-47-01-0025" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHENG</surname><given-names>YUSHENG</given-names></name><xref rid="af1-ijo-47-01-0025" ref-type="aff">1</xref><xref rid="af2-ijo-47-01-0025" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>HE</surname><given-names>WENTING</given-names></name><xref rid="af1-ijo-47-01-0025" ref-type="aff">1</xref><xref rid="af2-ijo-47-01-0025" ref-type="aff">2</xref></contrib></contrib-group>
<aff id="af1-ijo-47-01-0025">
<label>1</label>The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China</aff>
<aff id="af2-ijo-47-01-0025">
<label>2</label>Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou, Gansu 730030, P.R. China</aff>
<author-notes>
<corresp id="c1-ijo-47-01-0025">Correspondence to: Professor Yumin Li, Key Laboratory of Digestive System Tumors of Gansu Province, The Second Hospital of Lanzhou University, 82 Cuiyingmen, Lanzhou, Gansu 730000, P.R. China, E-mail: <email>liym@lzu.edu.cn</email></corresp><fn id="fn1-ijo-47-01-0025">
<label>*</label>
<p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="collection">
<month>7</month>
<year>2015</year></pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>05</month>
<year>2015</year></pub-date>
<volume>47</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>34</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>01</month>
<year>2015</year></date>
<date date-type="accepted">
<day>08</day>
<month>04</month>
<year>2015</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2015, Spandidos Publications</copyright-statement>
<copyright-year>2015</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions>
<abstract>
<p>MicroRNAs (miRNAs) are recognized as an emerging class of master regulators that regulate human gene expression at the post-transcriptional level and are involved in many normal and pathological cellular processes. Mammalian basic HLH (helix-loop-helix)-PER-ARNT-SIM (bHLH-PAS) proteins are heterodimeric transcriptional regulators that sense and respond to environmental signals (such as chemical pollutants) or to physiological signals (for instance hypoxia). In the normal state, bHLH-PAS proteins are responsible for multiple critical aspects of physiology to ensure the cell accurate homeostasis, but dysregulation of these proteins has been shown to contribute to carcinogenic events such as tumor initiation, promotion, and progression. Increasing epidemiological and experimental studies have shown that bHLH-PAS proteins regulate a panel of miRNAs, whereas some miRNAs also target bHLH-PAS proteins. The interaction between miRNAs and certain bHLH-PAS proteins &#x0005B;hypoxia-inducible factor (HIF) and aryl hydrocarbon receptor (AHR)&#x0005D; is relevant to many vital events associated with tumorigenesis. This review will summarize recent findings on the interesting and complicated underlying mechanisms that miRNAs interact with HIFs or AHR in tumors, hopefully to benefit the discovery of novel drug-interfering targets for cancer therapy.</p></abstract>
<kwd-group>
<kwd>microRNA</kwd>
<kwd>bHLH-PAS protein</kwd>
<kwd>hypoxia-inducible factor</kwd>
<kwd>aryl hydrocarbon receptor</kwd>
<kwd>cancer</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="other">
<title>1. Introduction</title>
<p>miRNAs are small (18&#x02013;25 nucleotides) non-coding RNAs that degrade target mRNA or suppress its translation by specifically binding to the 3&#x02032; untranslated region (3&#x02032;UTR), thus playing a role of gene silencing (<xref rid="b1-ijo-47-01-0025" ref-type="bibr">1</xref>,<xref rid="b2-ijo-47-01-0025" ref-type="bibr">2</xref>). To date, &gt;1,400 different miRNAs have been found in humans and regulate &gt;30&#x00025; of mammalian gene expression (<xref rid="b3-ijo-47-01-0025" ref-type="bibr">3</xref>,<xref rid="b4-ijo-47-01-0025" ref-type="bibr">4</xref>). At baseline, miRNAs ensure accurate physiological functions, such as growth, development, differentiation and stress. While, abnormal expression induced by a variety of internal and external factors also plays a pivotal role in tumor origin, proliferation, migration and other pathological processes (<xref rid="b5-ijo-47-01-0025" ref-type="bibr">5</xref>,<xref rid="b6-ijo-47-01-0025" ref-type="bibr">6</xref>).</p>
<p>The bHLH-PAS proteins are heterodimeric transcription factors that form a subgroup of the bHLH superfamily. The bHLH-PAS proteins generally consist of two PAS domains that can sense and respond to environmental signals; for example benzo&#x0005B;<italic>a</italic>&#x0005D;pyrene (B&#x0005B;a&#x0005D;P), 2,3,7,8-tetrachlorodibenzo-r-dioxin (TCDD) or to physiological signals (such as hypoxia) (<xref rid="b7-ijo-47-01-0025" ref-type="bibr">7</xref>). The bHLH-PAS superfamily includes some very important transcription factors such as AHR, the AHR nuclear translocator (ARNT; also known as HIF1&#x003B2;), the AHR repressor (AHRR) and different HIFs. Members of the bHLH-PAS family play a broad range role in physiological and pathological processes and take part in multiple cellular signal pathways (<xref rid="b8-ijo-47-01-0025" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-ijo-47-01-0025" ref-type="bibr">10</xref>). Recent studies have discovered several selective agonists and antagonists that directly target this multifunctional family, presenting a huge potential as an antitumor drug target (<xref rid="b11-ijo-47-01-0025" ref-type="bibr">11</xref>,<xref rid="b12-ijo-47-01-0025" ref-type="bibr">12</xref>).</p>
<p>In recent years, many studies have shown that AHR and HIF can play pro-tumor or antitumor roles. Moreover, the role of miRNAs in tumor origin and development are also focus of attention. Thus, this review focuses on the complicated interactional mechanisms between miRNAs and certain bHLH-PAS proteins (the HIF and AHR) in many vital events relevant to multiple forms of tumors.</p></sec>
<sec sec-type="other">
<title>2. miRNAs and bHLH-PAS proteins</title>
<p>Epidemiological and experimental research provides substantial support for the association between bHLH-PAS proteins and miRNAs in cancer (<xref rid="b13-ijo-47-01-0025" ref-type="bibr">13</xref>) (<xref rid="f1-ijo-47-01-0025" ref-type="fig">Fig. 1</xref>, <xref rid="tI-ijo-47-01-0025" ref-type="table">Tables I</xref> and <xref rid="tII-ijo-47-01-0025" ref-type="table">II</xref>). miR-210 is a very important HIF associated miRNA that can be found consistently dysregulated in multiple forms of tumors and is involved in many HIFs associated cellular signal pathways (<xref rid="b14-ijo-47-01-0025" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-ijo-47-01-0025" ref-type="bibr">16</xref>). Similarly to the transcriptional mechanism of protein encoding genes, the transcription of miRNAs from miRNA genes is regulated by transcription factors, including HIFs and AHR. In breast cancer cells, miRNA sequencing data analysis identified 41 miRNAs significantly upregulated and 28 down-regulated under hypoxia. Moreover, study on the transcriptional regulation of miRNA expression by HIFs further illustrated that significantly upregulated miR-210-3p contained a HIF-binding site at its promoter region (<xref rid="b17-ijo-47-01-0025" ref-type="bibr">17</xref>). The promoter regions of miR-155 and miR-373 genes were also found containing HIF-binding site by which hypoxia could promote the transcription of related miRNAs (<xref rid="b18-ijo-47-01-0025" ref-type="bibr">18</xref>). In addition, several transcripts involved in miRNA expressional processes were found to be regulated by hypoxia. For instance, HIF1 regulated the expression of two miRNA transcripts: DICER and AGO4 (<xref rid="b17-ijo-47-01-0025" ref-type="bibr">17</xref>). On the other hand, some miRNAs target HIFs and AHR are involved in the regulation of members in HIFs and AHR signal pathways. Hypoxia regulates the expression of miR-20b, miR-199, miR-210 and miR-424 which can directly target HIFs or control its expression (<xref rid="b19-ijo-47-01-0025" ref-type="bibr">19</xref>&#x02013;<xref rid="b23-ijo-47-01-0025" ref-type="bibr">23</xref>).</p>
<p>In regards to AHR, Gordon <italic>et al</italic> reported that the environmental carcinogen B&#x0005B;a&#x0005D;P and TCDD, the xenobiotic AHR ligands, upregulated the expression of a variety of miRNAs in multiple myeloma cells. Importantly, the miR-25 promoter was activated by both B&#x0005B;a&#x0005D;P and TCDD, and this response was mediated by AhR (<xref rid="b24-ijo-47-01-0025" ref-type="bibr">24</xref>).</p></sec>
<sec sec-type="other">
<title>3. The potential mechanisms</title>
<sec>
<title>Proliferation and cell cycle</title>
<p>miR-210 and miR-21 are upregulated by HIF1&#x003B1; in a variety of tumors and take part in regulating tumor growth, proliferation and the cell cycle (<xref rid="b25-ijo-47-01-0025" ref-type="bibr">25</xref>). For example, the overexpression of miR-210 induced by HIF1&#x003B1; could be found in melanoma and lung cancer cells, upregulated miR-210 inhibited proliferation of lung cancer (<xref rid="b26-ijo-47-01-0025" ref-type="bibr">26</xref>). While Li <italic>et al</italic> reported that upregulated miR-210 facilitated tumor proliferation in epithelial ovarian cancer via targeting protein tyrosine phosphatase, non-receptor type 1 (PTPN1) (<xref rid="b27-ijo-47-01-0025" ref-type="bibr">27</xref>). In addition, inhibition of miR-210 caused cell cycle arrest prior to G2/M in melanoma (<xref rid="b28-ijo-47-01-0025" ref-type="bibr">28</xref>). miR-21 promoted proliferation and overrode hypoxia-induced cell cycle arrest at the G1/S transition (<xref rid="b29-ijo-47-01-0025" ref-type="bibr">29</xref>). <italic>In vitro</italic>, <italic>in vivo</italic> and pathological study showed that HIF1&#x003B1; was a direct target of miR-199 family, downregulated miR-199a was essential for hypoxia induced proliferation by derepressing the expression of HIF1&#x003B1; and influencing HIF1&#x003B1; mediated the glycolytic pathway in non-small cell lung cancer (NSCLC) (<xref rid="b30-ijo-47-01-0025" ref-type="bibr">30</xref>). While the overexpression of miR-199a and miR-199b, by using virus vectors, significantly downregulated HIF1&#x003B1; and suppressed cell proliferation in hepatocellular carcinoma (HCC) (<xref rid="b31-ijo-47-01-0025" ref-type="bibr">31</xref>) and prostate cancer (<xref rid="b32-ijo-47-01-0025" ref-type="bibr">32</xref>), respectively. Zhang <italic>et al</italic> demonstrated that miR-135b promoted tumor proliferation and colony formation through targeting factor inhibiting HIF (FIH) and activating HIF1&#x003B1; in head and neck squamous cell carcinoma (HNSCC) (<xref rid="b33-ijo-47-01-0025" ref-type="bibr">33</xref>). In addition, Taguchi <italic>et al</italic> showed that overexpression of miR-17&#x02013;92 induced by c-myc directly targeted HIF1&#x003B1; and played a role in cancer cell proliferation (<xref rid="b34-ijo-47-01-0025" ref-type="bibr">34</xref>).</p>
<p>Regarding AHR, Trivellin <italic>et al</italic> reported that miR-107 was overexpressed in pituitary adenoma samples, and the overexpression of miR-107 inhibited cell proliferation through directly targeting the AHR-interacting protein (AIP) (<xref rid="b35-ijo-47-01-0025" ref-type="bibr">35</xref>). When exposed to B&#x0005B;a&#x0005D;P, the expression levels of miR-320 and miR-494 were upregulated and repressed the expression of cyclin-dependent kinase 6 (CDK6), which regulates cell cycle progression by impacting G1/S transition (<xref rid="b36-ijo-47-01-0025" ref-type="bibr">36</xref>). Yuan <italic>et al</italic> identified ARNT as a novel target of miR-221, and found that delivery of the miR-221 mimics into primary hepatocytes and overexpression of miR-221 mediated by adeno-associated virus in the mouse liver could significantly promote proliferation by targeting ARNT, and suppressed the cell cycle regulator p27 (<xref rid="b37-ijo-47-01-0025" ref-type="bibr">37</xref>).</p></sec>
<sec>
<title>Angiogenesis</title>
<p>Angiogenesis plays a key role in tumor growth and metastasis (<xref rid="b38-ijo-47-01-0025" ref-type="bibr">38</xref>). bHLH-PAS proteins regulate several angiogenic growth factors through transcriptional modulation, such as the well-known angiogenesis inducer, the vascular endothelial growth factor (VEGF) (<xref rid="b39-ijo-47-01-0025" ref-type="bibr">39</xref>&#x02013;<xref rid="b41-ijo-47-01-0025" ref-type="bibr">41</xref>). On one hand, bHLH-PAS proteins contribute to vascular homeostasis under adverse environment including toxins and hypoxia, on the other, bHLH-PAS proteins promote angiogenesis in various types of tumors.</p>
<p>He <italic>et al</italic> found that miR-199a-5p expression levels were significantly downregulated in arsenic transformed cells, and demonstrated that arsenic promoted tumor growth and angiogenesis due to low expression of miR-199a-5p caused loss of control on its direct targets HIF1&#x003B1; and its downstream target COX-2 <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="b19-ijo-47-01-0025" ref-type="bibr">19</xref>). In low-oxygen conditions, miR-320 was downregulated by HIF1&#x003B1; in human umbilical vein endothelial cells (HUVECs) and attenuated the inhibitory effect on its target Neuropilin 1, an important regulator of angiogenesis, thus promoting angiogenesis (<xref rid="b42-ijo-47-01-0025" ref-type="bibr">42</xref>). The interaction between HIF and VEGF regulates tumor angiogenesis and enables tumor cells to adapt to different oxygen concentrations (<xref rid="b43-ijo-47-01-0025" ref-type="bibr">43</xref>). Recent studies illustrate miRNAs are also involved in the HIF/VEGF network (<xref rid="b20-ijo-47-01-0025" ref-type="bibr">20</xref>,<xref rid="b44-ijo-47-01-0025" ref-type="bibr">44</xref>,<xref rid="b45-ijo-47-01-0025" ref-type="bibr">45</xref>). For instance, miR-199a and miR-125b were downregulated in ovarian cancer tissues and cell lines and negatively correlated with tumor angiogenesis via HIF1&#x003B1;/VEGF pathway (<xref rid="b46-ijo-47-01-0025" ref-type="bibr">46</xref>). Overexpression of miR-22 inhibited HIF1&#x003B1; expression, repressing VEGF production during hypoxia. Conversely, knockdown of endogenous miR-22 enhanced hypoxia-induced expression of HIF1&#x003B1; and VEGF (<xref rid="b47-ijo-47-01-0025" ref-type="bibr">47</xref>). In addition to the inhibitory effects of miR-503 on angiogenesis through directly targeting two most potent angiogenic factors: fibroblast growth factor-2 (FGF2) and VEGFA (<xref rid="b48-ijo-47-01-0025" ref-type="bibr">48</xref>), miR-128 and miR-145 were demonstrated to attenuate tumor angiogenesis by targeting p70S6K1 and suppressing the downstream signaling molecules HIF1 and VEGF (<xref rid="b49-ijo-47-01-0025" ref-type="bibr">49</xref>,<xref rid="b50-ijo-47-01-0025" ref-type="bibr">50</xref>). When induced by hypoxia, miR-519c resulted in a significant decrease of HIF1&#x003B1; protein levels and reduced the tube formation of HUVECs. Similarly, inhibition of miR-519c by antagonist increased the level of HIF1&#x003B1; protein and enhanced angiogenic activity (<xref rid="b51-ijo-47-01-0025" ref-type="bibr">51</xref>). Moreover, increased HIF2&#x003B1; in hypoxia induced the repression of miR-15&#x02013;16 and promoted angiogenesis in colorectal carcinoma cell lines (<xref rid="b52-ijo-47-01-0025" ref-type="bibr">52</xref>).</p></sec>
<sec>
<title>Invasion and metastasis</title>
<p>Zhang <italic>et al</italic> found that AHR modulator TCDD and the 6-methyl-1,3,-trichlorodibenzofuran (MCDF) inhibited breast cancer cell invasion by inducing the high expression of miR-335 and repressing a target gene of miR-335: SRY-related high mobility group box 4 (SOX4). Knocking down the AHR inhibited the effects of TCDD and MCDF on miR-335 and SOX4 expression, thus confirming AHR-miR-335 interact to inhibit breast cancer cell metastasis (<xref rid="b53-ijo-47-01-0025" ref-type="bibr">53</xref>). Interestingly, SOX4 was also a target gene of miR-138, the expression of miR-138 inhibited ovarian cancer metastasis via suppressing SOX4 and HIF1&#x003B1;, and overexpression of SOX4 and HIF1&#x003B1; effectively reversed the miR-138 mediated suppression of cell metastasis (<xref rid="b54-ijo-47-01-0025" ref-type="bibr">54</xref>). In low-oxygen conditions, decreased miR-199a facilitated the metastasis of ovarian cancer cells due to attenuating the inhibitory effect on HIF1&#x003B1; and HIF2&#x003B1; (<xref rid="b55-ijo-47-01-0025" ref-type="bibr">55</xref>). Zhang <italic>et al</italic> reported that downregulated miR-145 inversely correlated with HIF2&#x003B1; expression in all 20 neuroblastoma samples. While overexpression of miR-145 suppressed tumor invasion and metastasis <italic>in vitro</italic> and <italic>in vivo</italic> by directly targeting HIF2&#x003B1; and promoting the expression of cyclin D1, VEGF and matrix metalloproteinase-14 (MMP-14) (<xref rid="b56-ijo-47-01-0025" ref-type="bibr">56</xref>). miR-23b was demonstrated to induce tumor metastasis by targeting von Hippel-Lindau (VHL) and activating the HIF1&#x003B1;/VEGF and &#x003B2;-catenin/Tcf-4 signaling pathways (<xref rid="b57-ijo-47-01-0025" ref-type="bibr">57</xref>). In addition, downregulation of miR-101 by HIF1&#x003B1;/HIF1&#x003B2; enhanced invasion and migration of prostate cancer cells, which may be attributed to the reduced inhibition of enhancer of zeste homolog 2 (Ezh2) by miR-101 (<xref rid="b58-ijo-47-01-0025" ref-type="bibr">58</xref>).</p></sec>
<sec>
<title>Apoptosis</title>
<p>As a signature miRNA of hypoxia, miR-210 promoted neuroblastoma cell apoptosis via specifically decreasing anti-apoptotic Bcl-2 (<xref rid="b59-ijo-47-01-0025" ref-type="bibr">59</xref>). The upregulation of miR-21 avoided cell apoptosis in pancreatic cancer cells and ovarian cancer cells (<xref rid="b27-ijo-47-01-0025" ref-type="bibr">27</xref>,<xref rid="b29-ijo-47-01-0025" ref-type="bibr">29</xref>). While lentiviral-mediated downregulation of miR-210 expression in hypoxic HCC cells significantly induced apoptosis through directly targeting apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3) (<xref rid="b60-ijo-47-01-0025" ref-type="bibr">60</xref>). In addition, Shang <italic>et al</italic> showed that miR-199b negatively regulated HIF1&#x003B1; by targeting its 3&#x02032;UTR and promoted apoptosis (<xref rid="b32-ijo-47-01-0025" ref-type="bibr">32</xref>).</p>
<p>Triggering the AhR by agonists such as TCDD and B&#x0005B;a&#x0005D; P decreased expression levels of miR-196a depending on AhR response element (AhRE) binding. While suppressing AHR expression induced miR-196a was able to promote cell apoptosis (<xref rid="b61-ijo-47-01-0025" ref-type="bibr">61</xref>).</p></sec>
<sec>
<title>Metabolism</title>
<p>In low-oxygen conditions, Louis Pasteur identified a metabolic shift from mitochondrial oxidative phosphorylation to glycolysis that result from repression of the tricarboxylic acid (TCA) cycle, mitochondrial electron transport, and oxidative phosphorylation (<xref rid="b62-ijo-47-01-0025" ref-type="bibr">62</xref>). Upregulated miR-210 by HIF plays a pivotal role in the regulation of the components that are necessary for this &#x02018;Pasteur effect&#x02019;, which can minimize the impact of hypoxia on energy production and benefit tumor growth (<xref rid="b63-ijo-47-01-0025" ref-type="bibr">63</xref>,<xref rid="b64-ijo-47-01-0025" ref-type="bibr">64</xref>). miR-210 caused a shift to glycolysis by controlling a series of components of mitochondrial oxidative phosphorylation, these components included iron-sulfur cluster scaffold homolog (ISCU) (<xref rid="b63-ijo-47-01-0025" ref-type="bibr">63</xref>), COX10 (<xref rid="b16-ijo-47-01-0025" ref-type="bibr">16</xref>), mitochondrial complex I and aconitase (<xref rid="b65-ijo-47-01-0025" ref-type="bibr">65</xref>,<xref rid="b66-ijo-47-01-0025" ref-type="bibr">66</xref>), subunit D of succinate dehydrogenase complex (SDHD) (<xref rid="b67-ijo-47-01-0025" ref-type="bibr">67</xref>), glycerol-3-phosphate dehydrogenase 1-like (GPD1-L) (<xref rid="b68-ijo-47-01-0025" ref-type="bibr">68</xref>). In addition to miR-210, miR-183 upregulated HIF1&#x003B1; by targeting isocitrate dehydrogenase 2 (IDH2): mitochondrial enzymes catalyze the conversion of isocitrate to &#x003B1;-ketoglutarate in TCA cycle (<xref rid="b69-ijo-47-01-0025" ref-type="bibr">69</xref>). Downregulated HIF1&#x003B1; by miR-99a in hepatocarcinoma cells inhibited insulin-induced glucose consumption by suppressing pyruvate kinase M2 (PKM2), a rate-limiting enzyme in the glycolytic pathway (<xref rid="b70-ijo-47-01-0025" ref-type="bibr">70</xref>). miR-203 negatively regulated AHR expression and had a putative binding site in the 3&#x02032;UTR of indoleamine 2,3-dioxygenase (IDO) (<xref rid="b71-ijo-47-01-0025" ref-type="bibr">71</xref>). IDO is a rate-limiting enzyme in extrahepatic catabolism of tryptophan, thus miR-203 may be involved in AHR/IDO axis-mediated metabolism of tryptophan (<xref rid="b72-ijo-47-01-0025" ref-type="bibr">72</xref>).</p></sec>
<sec>
<title>Inflammation and immunity</title>
<p>Wang <italic>et al</italic> reported that there was a negative-feedback between miR-210 and HIF1&#x003B1; and they could regulate each other. When induced by hypoxia, miR-210 negatively regulated HIF1&#x003B1; expression and TH17 cell differentiation through reducing HIF1&#x003B1; transcript abundance and the proportion of cells producing inflammatory cytokines, which could limit immunopathology (<xref rid="b73-ijo-47-01-0025" ref-type="bibr">73</xref>). miR-17 and miR-20a mediated post-transcriptional suppression of HIF1&#x003B1; and HIF2&#x003B1; expression in tumor-associated monocytes and macrophages and played an important role during a wide range of cellular physiological as well as pathophysiological processes such as monocyte-to-macrophage differentiation (<xref rid="b74-ijo-47-01-0025" ref-type="bibr">74</xref>,<xref rid="b75-ijo-47-01-0025" ref-type="bibr">75</xref>). Csak <italic>et al</italic> revealed that downregulation of miR-122 attenuated the inhibitory effect on HIF1&#x003B1; and played a pathogenic role in steatohepatitis (<xref rid="b76-ijo-47-01-0025" ref-type="bibr">76</xref>).</p>
<p>Bleck <italic>et al</italic> reported that upregulated miR-375 by environmental pollutants could target AhR and downregulate its expression, thus regulating a pivotal cytokine, thymic stromal lymphopoietin (TSLP), which associated with innate and Th2 adaptive immune disorders (<xref rid="b77-ijo-47-01-0025" ref-type="bibr">77</xref>). The overexpression of miR-132/212 cluster induced by AHR promoted differentiation of Th17 cells by targeting a negative regulator of Th17 differentiation, the B-cell lymphoma 6 (<xref rid="b78-ijo-47-01-0025" ref-type="bibr">78</xref>).</p></sec>
<sec>
<title>Stem cells</title>
<p>Stem cells are found in all multicellular organisms, that can self-renew and differentiate into diverse specialized cell types, and cancer stem cells are critical drivers of tumor progression (<xref rid="b38-ijo-47-01-0025" ref-type="bibr">38</xref>). Yang <italic>et al</italic> found that hypoxia led to induction of HIF2&#x003B1; and miR-210 in glioma stem cells (GSCs), while knocking down of miR-210 decreased stemness, viability, neurosphere formation capacity, invasive capacity and induced differentiation, apoptosis, G0/G1 cell cycle arrest of hypoxic GSCs, and participated in regulating myc-antagonist (MNT) protein expression and caspase-3/7 activity (<xref rid="b79-ijo-47-01-0025" ref-type="bibr">79</xref>). The enhancement of peroxisome proliferator activated receptor-&#x003B1; (PPAR&#x003B1;) and HIF1&#x003B1; interplay in breast cancer stem cells sustained expression of the pro-inflammatory cytokine interleukin-6 (IL-6), the hypoxia survival factor carbonic anhydrase IX and the plasma lipid carrier apolipoprotein E. Moreover, the PPAR&#x003B1;/HIF1&#x003B1; interplay was regulated by miR-130b through targeting DDX6 (a HIF1&#x003B1; translation inhibitory protein) and miR-17-5p via directly targeting PPAR&#x003B1; (<xref rid="b80-ijo-47-01-0025" ref-type="bibr">80</xref>). Overexpression of miR-21 induced by HIF1&#x003B1; played a positive role for epithelial-mesenchymal transition (EMT), invasion and migration of breast cancer stem cell-like cells (<xref rid="b81-ijo-47-01-0025" ref-type="bibr">81</xref>).</p></sec></sec>
<sec sec-type="other">
<title>4. Clinical application</title>
<p>The resistance of hypoxic cells to radiotherapy and chemotherapy is a major problem in the treatment of cancer. Induction of miR-210 by HIF1&#x003B1; in hypoxia conferred resistance to radiation via rapidly repairing DNA double-strand breaks after radiation in NSCLC cells (<xref rid="b14-ijo-47-01-0025" ref-type="bibr">14</xref>). The induction of miR-210-3p by HIF1&#x003B1; in GBM cells showed increased resistance to temozolomide (a chemotherapeutic drug) mediated death while miR-210-3p inhibition made cells more sensitive (<xref rid="b13-ijo-47-01-0025" ref-type="bibr">13</xref>). Inhibition of miR-566 was demonstrated to sensitize GBM cells to nimo-tuzumab by targeting VHL and activating the &#x003B2;-catenin/HIF1&#x003B1; complex which can suppress the activity of epidermal growth factor receptor (EGFR) pathway (<xref rid="b82-ijo-47-01-0025" ref-type="bibr">82</xref>). Bao <italic>et al</italic> reported that the treatment of pancreatic cancer cells with a novel synthetic derivative of curcumin showed an obvious antitumor effect through decreasing gene expression of miR-21, miR-210, IL-6, HIF1&#x003B1;, VEGF under hypoxia (<xref rid="b83-ijo-47-01-0025" ref-type="bibr">83</xref>,<xref rid="b84-ijo-47-01-0025" ref-type="bibr">84</xref>). In low-oxygen conditions, overexpression of miR-155 induced by HIF1&#x003B1; enhanced radioresistance in lung cancer cells and correlated with poor patient prognosis (<xref rid="b85-ijo-47-01-0025" ref-type="bibr">85</xref>). Pyrrolopyrazine metabolite of oltipraz, a cancer chemopreventive agent, was found to play its antineo-plastic function via inducing miR-199a-5p and miR-20a and these two miRNAs mediated inhibition of HIF1&#x003B1; by preventing its <italic>de novo</italic> synthesis (<xref rid="b86-ijo-47-01-0025" ref-type="bibr">86</xref>). A case-control study including 35 matched HCCs and cirrhosis tissues showed that under-expressed miR-199b regulated by the upregulation of HIF1&#x003B1; in HCCs was inversely correlated with survival and directly correlated with the malignant status of HCC patients (<xref rid="b87-ijo-47-01-0025" ref-type="bibr">87</xref>).</p>
<p>Hu <italic>et al</italic> demonstrated that upregulation of miR-302 in response to tranilast treatment was dependent on AHR, which was able to bind to miR-302 promoter and active its expression (<xref rid="b88-ijo-47-01-0025" ref-type="bibr">88</xref>). Transcriptionally activated miR-125b by nuclear factor erythroid-2-related factor 2 (Nrf2) served as an inhibitor of AhRR and attenuated its control on AhR, thus, upregulated AhR inhibited p53 activity by targeting an inhibitor of p53 (Mdm2) and contributed to protecting the kidneys from cisplatin-induced injury (<xref rid="b89-ijo-47-01-0025" ref-type="bibr">89</xref>).</p></sec>
<sec sec-type="other">
<title>5. Conclusions and future directions</title>
<p>There is increasing evidence that the bHLH-PAS proteins and its ligands play important roles in cell normal homeostasis and malignant tumor formation. miRNAs can consistently and rapidly sense and respond to environmental and physiological signals (such as B&#x0005B;a&#x0005D;P and hypoxia) by regulating multi-variety of genes and influencing numerous components of cellular signaling pathways extensively and simultaneously, thus research on the interactional role of miRNAs and bHLH-PAS proteins is worthy to clarify the mechanism that underlies the regulation of these environmental and physiological signals. However, the complicated physiological and pathophysiological molecular mechanisms between miRNAs and bHLH-PAS proteins are still unclear. Therefore, further study is needed to uncover the basic mechanisms and should focus on the following directions. First, we need to find more miRNAs and demonstrate their target genes and functions involved in bHLH-PAS proteins. Then, inflammation and stem cells are very valuable and promising fields in cancer. Further in-depth investigations are needed to understand the underlying mechanisms of this interaction in stem cell transformation, CSCs maintainence, and the relationship between inflammation and cancer. The ultimate goal is to look for specific diagnostic markers and selective preventive and therapeutic drugs thus promoting anticancer pharmaceutical development and benefit the prognosis of cancer patients.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the National Natural Science Foundation of China (grant no. 31270532) and Central College Basic Scientific Research Foundation of Lanzhou University (grant no. lzujbky-2013-m04).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ijo-47-01-0025"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>EC</given-names></name></person-group><article-title>Micro RNAs are complementary to 3&#x02032; UTR sequence motifs that mediate negative post-transcriptional regulation</article-title><source>Nat Genet</source><volume>30</volume><fpage>363</fpage><lpage>364</lpage><year>2002</year><pub-id pub-id-type="doi">10.1038/ng865</pub-id><pub-id pub-id-type="pmid">11896390</pub-id></element-citation></ref>
<ref id="b2-ijo-47-01-0025"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selbach</surname><given-names>M</given-names></name><name><surname>Schwanh&#x000E4;usser</surname><given-names>B</given-names></name><name><surname>Thierfelder</surname><given-names>N</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name></person-group><article-title>Widespread changes in protein synthesis induced by microRNAs</article-title><source>Nature</source><volume>455</volume><fpage>58</fpage><lpage>63</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/nature07228</pub-id><pub-id pub-id-type="pmid">18668040</pub-id></element-citation></ref>
<ref id="b3-ijo-47-01-0025"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isomoto</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Kunizaki</surname><given-names>M</given-names></name><name><surname>Hidaka</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Hisatsune</surname><given-names>J</given-names></name><name><surname>Nakashima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Interweaving microRNAs and proinflammatory cytokines in gastric mucosa with reference to H. pylori infection</article-title><source>J Clin Immunol</source><volume>32</volume><fpage>290</fpage><lpage>299</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s10875-011-9626-3</pub-id></element-citation></ref>
<ref id="b4-ijo-47-01-0025"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoof</surname><given-names>CR</given-names></name><name><surname>Botelho</surname><given-names>EL</given-names></name><name><surname>Izzotti</surname><given-names>A</given-names></name><name><surname>Vasques Ldos</surname><given-names>R</given-names></name></person-group><article-title>MicroRNAs in cancer treatment and prognosis</article-title><source>Am J Cancer Res</source><volume>2</volume><fpage>414</fpage><lpage>433</lpage><year>2012</year><pub-id pub-id-type="pmid">22860232</pub-id><pub-id pub-id-type="pmcid">3410578</pub-id></element-citation></ref>
<ref id="b5-ijo-47-01-0025"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendell</surname><given-names>JT</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><article-title>MicroRNAs in stress signaling and human disease</article-title><source>Cell</source><volume>148</volume><fpage>1172</fpage><lpage>1187</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.005</pub-id><pub-id pub-id-type="pmid">22424228</pub-id><pub-id pub-id-type="pmcid">3308137</pub-id></element-citation></ref>
<ref id="b6-ijo-47-01-0025"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tili</surname><given-names>E</given-names></name><name><surname>Michaille</surname><given-names>JJ</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer</article-title><source>Immunol Rev</source><volume>253</volume><fpage>167</fpage><lpage>184</lpage><year>2013</year><pub-id pub-id-type="doi">10.1111/imr.12050</pub-id><pub-id pub-id-type="pmid">23550646</pub-id></element-citation></ref>
<ref id="b7-ijo-47-01-0025"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denison</surname><given-names>MS</given-names></name><name><surname>Soshilov</surname><given-names>AA</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>DeGroot</surname><given-names>DE</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name></person-group><article-title>Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor</article-title><source>Toxicol Sci</source><volume>124</volume><fpage>1</fpage><lpage>22</lpage><year>2011</year><pub-id pub-id-type="doi">10.1093/toxsci/kfr218</pub-id><pub-id pub-id-type="pmid">21908767</pub-id><pub-id pub-id-type="pmcid">3196658</pub-id></element-citation></ref>
<ref id="b8-ijo-47-01-0025"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>BE</given-names></name><name><surname>Hogenesch</surname><given-names>JB</given-names></name><name><surname>Bradfield</surname><given-names>CA</given-names></name></person-group><article-title>Mammalian Per-Arnt-Sim proteins in environmental adaptation</article-title><source>Annu Rev Physiol</source><volume>72</volume><fpage>625</fpage><lpage>645</lpage><year>2010</year><pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135922</pub-id><pub-id pub-id-type="pmid">20148691</pub-id></element-citation></ref>
<ref id="b9-ijo-47-01-0025"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Role of aryl hydrocarbon receptor in cancer</article-title><source>Biochim Biophys Acta</source><volume>1836</volume><fpage>197</fpage><lpage>210</lpage><year>2013</year><pub-id pub-id-type="pmid">23711559</pub-id></element-citation></ref>
<ref id="b10-ijo-47-01-0025"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>YF</given-names></name><name><surname>Piazza</surname><given-names>GA</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-regulated microRNAs in human cancer</article-title><source>Acta Pharmacol Sin</source><volume>34</volume><fpage>336</fpage><lpage>341</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/aps.2012.195</pub-id><pub-id pub-id-type="pmid">23377548</pub-id><pub-id pub-id-type="pmcid">3587916</pub-id></element-citation></ref>
<ref id="b11-ijo-47-01-0025"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>MP</given-names></name><name><surname>Hicks</surname><given-names>KO</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Hypoxia-directed drug strategies to target the tumor microenvironment</article-title><source>Adv Exp Med Biol</source><volume>772</volume><fpage>111</fpage><lpage>145</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/978-1-4614-5915-6_6</pub-id></element-citation></ref>
<ref id="b12-ijo-47-01-0025"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safe</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SO</given-names></name><name><surname>Jin</surname><given-names>UH</given-names></name></person-group><article-title>Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target</article-title><source>Toxicol Sci</source><volume>135</volume><fpage>1</fpage><lpage>16</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/toxsci/kft128</pub-id><pub-id pub-id-type="pmid">23771949</pub-id><pub-id pub-id-type="pmcid">3748760</pub-id></element-citation></ref>
<ref id="b13-ijo-47-01-0025"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>R</given-names></name><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Jha</surname><given-names>P</given-names></name><name><surname>Dwivedi</surname><given-names>V</given-names></name><name><surname>Sarkar</surname><given-names>C</given-names></name><name><surname>Kulshreshtha</surname><given-names>R</given-names></name></person-group><article-title>Hypoxic signature of microRNAs in glioblastoma: Insights from small RNA deep sequencing</article-title><source>BMC Genomics</source><volume>15</volume><fpage>686</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2164-15-686</pub-id><pub-id pub-id-type="pmid">25129238</pub-id><pub-id pub-id-type="pmcid">4148931</pub-id></element-citation></ref>
<ref id="b14-ijo-47-01-0025"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>Doyen</surname><given-names>J</given-names></name><name><surname>Parks</surname><given-names>SK</given-names></name><name><surname>Bertero</surname><given-names>T</given-names></name><name><surname>Paye</surname><given-names>A</given-names></name><name><surname>Cardinaud</surname><given-names>B</given-names></name><name><surname>Gounon</surname><given-names>P</given-names></name><name><surname>Lacas-Gervais</surname><given-names>S</given-names></name><name><surname>No&#x000EB;l</surname><given-names>A</given-names></name><name><surname>Pouyss&#x000E9;gur</surname><given-names>J</given-names></name><etal/></person-group><article-title>MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines</article-title><source>Cell Death Dis</source><volume>4</volume><fpage>e544</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cddis.2013.71</pub-id><pub-id pub-id-type="pmid">23492775</pub-id><pub-id pub-id-type="pmcid">3615727</pub-id></element-citation></ref>
<ref id="b15-ijo-47-01-0025"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakada</surname><given-names>C</given-names></name><name><surname>Tsukamoto</surname><given-names>Y</given-names></name><name><surname>Matsuura</surname><given-names>K</given-names></name><name><surname>Nguyen</surname><given-names>TL</given-names></name><name><surname>Hijiya</surname><given-names>N</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><name><surname>Mimata</surname><given-names>H</given-names></name><name><surname>Seto</surname><given-names>M</given-names></name><name><surname>Moriyama</surname><given-names>M</given-names></name></person-group><article-title>Overexpression of miR-210, a downstream target of HIF1&#x003B1;, causes centrosome amplification in renal carcinoma cells</article-title><source>J Pathol</source><volume>224</volume><fpage>280</fpage><lpage>288</lpage><year>2011</year><pub-id pub-id-type="doi">10.1002/path.2860</pub-id><pub-id pub-id-type="pmid">21465485</pub-id></element-citation></ref>
<ref id="b16-ijo-47-01-0025"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Luthra</surname><given-names>R</given-names></name></person-group><article-title>Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression</article-title><source>Oncogene</source><volume>29</volume><fpage>4362</fpage><lpage>4368</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/onc.2010.193</pub-id><pub-id pub-id-type="pmid">20498629</pub-id></element-citation></ref>
<ref id="b17-ijo-47-01-0025"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Saini</surname><given-names>HK</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Choudhry</surname><given-names>H</given-names></name><name><surname>Reczko</surname><given-names>M</given-names></name><name><surname>Guerra-Assun&#x000E7;&#x000E3;o</surname><given-names>JA</given-names></name><name><surname>Tian</surname><given-names>YM</given-names></name><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia</article-title><source>Mol Cancer</source><volume>13</volume><fpage>28</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1476-4598-13-28</pub-id><pub-id pub-id-type="pmid">24517586</pub-id><pub-id pub-id-type="pmcid">3928101</pub-id></element-citation></ref>
<ref id="b18-ijo-47-01-0025"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruning</surname><given-names>U</given-names></name><name><surname>Cerone</surname><given-names>L</given-names></name><name><surname>Neufeld</surname><given-names>Z</given-names></name><name><surname>Fitzpatrick</surname><given-names>SF</given-names></name><name><surname>Cheong</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>CC</given-names></name><name><surname>Simpson</surname><given-names>DA</given-names></name><name><surname>Leonard</surname><given-names>MO</given-names></name><name><surname>Tambuwala</surname><given-names>MM</given-names></name><name><surname>Cummins</surname><given-names>EP</given-names></name><etal/></person-group><article-title>MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia</article-title><source>Mol Cell Biol</source><volume>31</volume><fpage>4087</fpage><lpage>4096</lpage><year>2011</year><pub-id pub-id-type="doi">10.1128/MCB.01276-10</pub-id><pub-id pub-id-type="pmid">21807897</pub-id><pub-id pub-id-type="pmcid">3187364</pub-id></element-citation></ref>
<ref id="b19-ijo-47-01-0025"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name></person-group><article-title>Chronic arsenic exposure and angiogenesis in human bronchial epithelial cells via the ROS/miR-199a-5p/HIF-1&#x003B1;/ COX-2 pathway</article-title><source>Environ Health Perspect</source><volume>122</volume><fpage>255</fpage><lpage>261</lpage><year>2014</year><pub-id pub-id-type="pmid">24413338</pub-id><pub-id pub-id-type="pmcid">3948041</pub-id></element-citation></ref>
<ref id="b20-ijo-47-01-0025"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>GM</given-names></name><name><surname>Feng</surname><given-names>ZH</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name></person-group><article-title>Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration</article-title><source>PLoS One</source><volume>4</volume><fpage>e7629</fpage><year>2009</year><pub-id pub-id-type="doi">10.1371/journal.pone.0007629</pub-id><pub-id pub-id-type="pmid">19893619</pub-id><pub-id pub-id-type="pmcid">2764090</pub-id></element-citation></ref>
<ref id="b21-ijo-47-01-0025"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rane</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Sayed</surname><given-names>D</given-names></name><name><surname>Vashistha</surname><given-names>H</given-names></name><name><surname>Malhotra</surname><given-names>A</given-names></name><name><surname>Sadoshima</surname><given-names>J</given-names></name><name><surname>Vatner</surname><given-names>DE</given-names></name><name><surname>Vatner</surname><given-names>SF</given-names></name><name><surname>Abdellatif</surname><given-names>M</given-names></name></person-group><article-title>Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes</article-title><source>Circ Res</source><volume>104</volume><fpage>879</fpage><lpage>886</lpage><year>2009</year><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.193102</pub-id><pub-id pub-id-type="pmid">19265035</pub-id><pub-id pub-id-type="pmcid">3332328</pub-id></element-citation></ref>
<ref id="b22-ijo-47-01-0025"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gits</surname><given-names>CM</given-names></name><name><surname>van Kuijk</surname><given-names>PF</given-names></name><name><surname>de Rijck</surname><given-names>JC</given-names></name><name><surname>Muskens</surname><given-names>N</given-names></name><name><surname>Jonkers</surname><given-names>MB</given-names></name><name><surname>van IJcken</surname><given-names>WF</given-names></name><name><surname>Mathijssen</surname><given-names>RH</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Sleijfer</surname><given-names>S</given-names></name><name><surname>Wiemer</surname><given-names>EA</given-names></name></person-group><article-title>MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3&#x003B1;</article-title><source>BMC Cancer</source><volume>14</volume><fpage>429</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1471-2407-14-429</pub-id></element-citation></ref>
<ref id="b23-ijo-47-01-0025"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>G</given-names></name><name><surname>Subramanian</surname><given-names>IV</given-names></name><name><surname>Adhikari</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Joshi</surname><given-names>HP</given-names></name><name><surname>Basi</surname><given-names>D</given-names></name><name><surname>Chandrashekhar</surname><given-names>YS</given-names></name><name><surname>Hall</surname><given-names>JL</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-&#x003B1; isoforms and promotes angiogenesis</article-title><source>J Clin Invest</source><volume>120</volume><fpage>4141</fpage><lpage>4154</lpage><year>2010</year><pub-id pub-id-type="doi">10.1172/JCI42980</pub-id><pub-id pub-id-type="pmid">20972335</pub-id><pub-id pub-id-type="pmcid">2964978</pub-id></element-citation></ref>
<ref id="b24-ijo-47-01-0025"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>MW</given-names></name><name><surname>Yan</surname><given-names>F</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Mazumder</surname><given-names>PB</given-names></name><name><surname>Xu-Monette</surname><given-names>ZY</given-names></name><name><surname>Zou</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Ramos</surname><given-names>KS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma</article-title><source>Mol Carcinog</source><month>May</month><day>6</day><year>2014</year><comment>(Epub ahead of print)</comment><pub-id pub-id-type="doi">10.1002/mc.22175</pub-id><pub-id pub-id-type="pmid">24798859</pub-id><pub-id pub-id-type="pmcid">4223015</pub-id></element-citation></ref>
<ref id="b25-ijo-47-01-0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Bennewith</surname><given-names>KL</given-names></name><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Welford</surname><given-names>SM</given-names></name><name><surname>Ang</surname><given-names>KK</given-names></name><name><surname>Story</surname><given-names>M</given-names></name><name><surname>Le</surname><given-names>QT</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name></person-group><article-title>Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation</article-title><source>Mol Cell</source><volume>35</volume><fpage>856</fpage><lpage>867</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.molcel.2009.09.006</pub-id><pub-id pub-id-type="pmid">19782034</pub-id><pub-id pub-id-type="pmcid">2782615</pub-id></element-citation></ref>
<ref id="b26-ijo-47-01-0025"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bian</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name></person-group><article-title>Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1&#x003B1;</article-title><source>Carcinogenesis</source><volume>32</volume><fpage>1881</fpage><lpage>1889</lpage><year>2011</year><pub-id pub-id-type="doi">10.1093/carcin/bgr218</pub-id><pub-id pub-id-type="pmid">21965273</pub-id><pub-id pub-id-type="pmcid">3220612</pub-id></element-citation></ref>
<ref id="b27-ijo-47-01-0025"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>You</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis</article-title><source>Int J Oncol</source><volume>44</volume><fpage>2111</fpage><lpage>2120</lpage><year>2014</year><pub-id pub-id-type="pmid">24715221</pub-id></element-citation></ref>
<ref id="b28-ijo-47-01-0025"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>HW</given-names></name><name><surname>Baxter</surname><given-names>LL</given-names></name><name><surname>Loftus</surname><given-names>SK</given-names></name><name><surname>Cronin</surname><given-names>JC</given-names></name><name><surname>Trivedi</surname><given-names>NS</given-names></name><name><surname>Borate</surname><given-names>B</given-names></name><name><surname>Pavan</surname><given-names>WJ</given-names></name></person-group><article-title>Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A</article-title><source>Pigment Cell Melanoma Res</source><volume>27</volume><fpage>777</fpage><lpage>787</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/pcmr.12255</pub-id><pub-id pub-id-type="pmid">24767210</pub-id><pub-id pub-id-type="pmcid">4150815</pub-id></element-citation></ref>
<ref id="b29-ijo-47-01-0025"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mace</surname><given-names>TA</given-names></name><name><surname>Collins</surname><given-names>AL</given-names></name><name><surname>Wojcik</surname><given-names>SE</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Lesinski</surname><given-names>GB</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name></person-group><article-title>Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells</article-title><source>J Surg Res</source><volume>184</volume><fpage>855</fpage><lpage>860</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.jss.2013.04.061</pub-id><pub-id pub-id-type="pmid">23726431</pub-id><pub-id pub-id-type="pmcid">3773267</pub-id></element-citation></ref>
<ref id="b30-ijo-47-01-0025"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>HD</given-names></name><name><surname>Liang</surname><given-names>HX</given-names></name><name><surname>Ni</surname><given-names>YF</given-names></name><name><surname>Ding</surname><given-names>ZH</given-names></name><name><surname>Ni</surname><given-names>GY</given-names></name><name><surname>Hua</surname><given-names>HW</given-names></name></person-group><article-title>MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting HIF1&#x003B1;</article-title><source>Mol Cell Biochem</source><volume>384</volume><fpage>173</fpage><lpage>180</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s11010-013-1795-3</pub-id><pub-id pub-id-type="pmid">24022342</pub-id></element-citation></ref>
<ref id="b31-ijo-47-01-0025"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>XQ</given-names></name><name><surname>Cheng</surname><given-names>HQ</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Bian</surname><given-names>CX</given-names></name><name><surname>Shi</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>JP</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Feng</surname><given-names>ZQ</given-names></name></person-group><article-title>Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma</article-title><source>Cell Biochem Biophys</source><volume>62</volume><fpage>237</fpage><lpage>244</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s12013-011-9263-8</pub-id></element-citation></ref>
<ref id="b32-ijo-47-01-0025"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Nie</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>miR199b suppresses expression of hypoxia-inducible factor 1&#x003B1; (HIF-1&#x003B1;) in prostate cancer cells</article-title><source>Int J Mol Sci</source><volume>14</volume><fpage>8422</fpage><lpage>8436</lpage><year>2013</year><pub-id pub-id-type="doi">10.3390/ijms14048422</pub-id><pub-id pub-id-type="pmid">23594994</pub-id><pub-id pub-id-type="pmcid">3645752</pub-id></element-citation></ref>
<ref id="b33-ijo-47-01-0025"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>ZJ</given-names></name><name><surname>Bian</surname><given-names>Y</given-names></name><name><surname>Kulkarni</surname><given-names>AB</given-names></name></person-group><article-title>MicroRNA-135b acts as a tumor promoter by targeting the hypoxia-inducible factor pathway in genetically defined mouse model of head and neck squamous cell carcinoma</article-title><source>Cancer Lett</source><volume>331</volume><fpage>230</fpage><lpage>238</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.canlet.2013.01.003</pub-id><pub-id pub-id-type="pmid">23340180</pub-id><pub-id pub-id-type="pmcid">3660136</pub-id></element-citation></ref>
<ref id="b34-ijo-47-01-0025"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Yanagisawa</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Matsuyama</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17&#x02013;92 microRNA cluster</article-title><source>Cancer Res</source><volume>68</volume><fpage>5540</fpage><lpage>5545</lpage><year>2008</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6460</pub-id><pub-id pub-id-type="pmid">18632605</pub-id></element-citation></ref>
<ref id="b35-ijo-47-01-0025"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivellin</surname><given-names>G</given-names></name><name><surname>Butz</surname><given-names>H</given-names></name><name><surname>Delhove</surname><given-names>J</given-names></name><name><surname>Igreja</surname><given-names>S</given-names></name><name><surname>Chahal</surname><given-names>HS</given-names></name><name><surname>Zivkovic</surname><given-names>V</given-names></name><name><surname>McKay</surname><given-names>T</given-names></name><name><surname>Pat&#x000F3;cs</surname><given-names>A</given-names></name><name><surname>Grossman</surname><given-names>AB</given-names></name><name><surname>Korbonits</surname><given-names>M</given-names></name></person-group><article-title>MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro</article-title><source>Am J Physiol Endocrinol Metab</source><volume>303</volume><fpage>E708</fpage><lpage>E719</lpage><year>2012</year><pub-id pub-id-type="doi">10.1152/ajpendo.00546.2011</pub-id><pub-id pub-id-type="pmid">22811466</pub-id></element-citation></ref>
<ref id="b36-ijo-47-01-0025"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo&#x0005B;a&#x0005D;pyrene</article-title><source>Toxicol In Vitro</source><volume>24</volume><fpage>928</fpage><lpage>935</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.tiv.2009.11.013</pub-id></element-citation></ref>
<ref id="b37-ijo-47-01-0025"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Loya</surname><given-names>K</given-names></name><name><surname>Rani</surname><given-names>B</given-names></name><name><surname>M&#x000F6;bus</surname><given-names>S</given-names></name><name><surname>Balakrishnan</surname><given-names>A</given-names></name><name><surname>Lamle</surname><given-names>J</given-names></name><name><surname>Cathomen</surname><given-names>T</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><etal/></person-group><article-title>MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration</article-title><source>Hepatology</source><volume>57</volume><fpage>299</fpage><lpage>310</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/hep.25984</pub-id></element-citation></ref>
<ref id="b38-ijo-47-01-0025"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref>
<ref id="b39-ijo-47-01-0025"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forsythe</surname><given-names>JA</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Iyer</surname><given-names>NV</given-names></name><name><surname>Agani</surname><given-names>F</given-names></name><name><surname>Leung</surname><given-names>SW</given-names></name><name><surname>Koos</surname><given-names>RD</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name></person-group><article-title>Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1</article-title><source>Mol Cell Biol</source><volume>16</volume><fpage>4604</fpage><lpage>4613</lpage><year>1996</year><pub-id pub-id-type="pmid">8756616</pub-id><pub-id pub-id-type="pmcid">231459</pub-id></element-citation></ref>
<ref id="b40-ijo-47-01-0025"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>AC</given-names></name><name><surname>Carvajal-Gonzalez</surname><given-names>JM</given-names></name><name><surname>Rico-Leo</surname><given-names>EM</given-names></name><name><surname>Fernandez-Salguero</surname><given-names>PM</given-names></name></person-group><article-title>Dioxin receptor deficiency impairs angiogenesis by a mechanism involving VEGF-A depletion in the endothelium and transforming growth factor-beta overexpression in the stroma</article-title><source>J Biol Chem</source><volume>284</volume><fpage>25135</fpage><lpage>25148</lpage><year>2009</year><pub-id pub-id-type="doi">10.1074/jbc.M109.013292</pub-id><pub-id pub-id-type="pmid">19617630</pub-id><pub-id pub-id-type="pmcid">2757217</pub-id></element-citation></ref>
<ref id="b41-ijo-47-01-0025"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceradini</surname><given-names>DJ</given-names></name><name><surname>Kulkarni</surname><given-names>AR</given-names></name><name><surname>Callaghan</surname><given-names>MJ</given-names></name><name><surname>Tepper</surname><given-names>OM</given-names></name><name><surname>Bastidas</surname><given-names>N</given-names></name><name><surname>Kleinman</surname><given-names>ME</given-names></name><name><surname>Capla</surname><given-names>JM</given-names></name><name><surname>Galiano</surname><given-names>RD</given-names></name><name><surname>Levine</surname><given-names>JP</given-names></name><name><surname>Gurtner</surname><given-names>GC</given-names></name></person-group><article-title>Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1</article-title><source>Nat Med</source><volume>10</volume><fpage>858</fpage><lpage>864</lpage><year>2004</year><pub-id pub-id-type="doi">10.1038/nm1075</pub-id><pub-id pub-id-type="pmid">15235597</pub-id></element-citation></ref>
<ref id="b42-ijo-47-01-0025"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Jao</surname><given-names>YC</given-names></name><name><surname>Hsieh</surname><given-names>IS</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Hong</surname><given-names>TM</given-names></name></person-group><article-title>miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1</article-title><source>Angiogenesis</source><volume>17</volume><fpage>247</fpage><lpage>260</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s10456-013-9394-1</pub-id></element-citation></ref>
<ref id="b43-ijo-47-01-0025"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Anand</surname><given-names>V</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name></person-group><article-title>Vascular endothelial growth factor signaling in hypoxia and inflammation</article-title><source>J Neuroimmune Pharmacol</source><volume>9</volume><fpage>142</fpage><lpage>160</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s11481-014-9531-7</pub-id><pub-id pub-id-type="pmid">24610033</pub-id><pub-id pub-id-type="pmcid">4048289</pub-id></element-citation></ref>
<ref id="b44-ijo-47-01-0025"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Carpenter</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Kung</surname><given-names>HF</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name></person-group><article-title>MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1&#x003B1; expression</article-title><source>PLoS One</source><volume>6</volume><fpage>e19139</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0019139</pub-id></element-citation></ref>
<ref id="b45-ijo-47-01-0025"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascio</surname><given-names>S</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>A</given-names></name><name><surname>Ferla</surname><given-names>R</given-names></name><name><surname>Surmacz</surname><given-names>E</given-names></name><name><surname>Gulotta</surname><given-names>E</given-names></name><name><surname>Amodeo</surname><given-names>V</given-names></name><name><surname>Bazan</surname><given-names>V</given-names></name><name><surname>Gebbia</surname><given-names>N</given-names></name><name><surname>Russo</surname><given-names>A</given-names></name></person-group><article-title>miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells</article-title><source>J Cell Physiol</source><volume>224</volume><fpage>242</fpage><lpage>249</lpage><year>2010</year><pub-id pub-id-type="pmid">20232316</pub-id></element-citation></ref>
<ref id="b46-ijo-47-01-0025"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>FS</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis</article-title><source>PLoS One</source><volume>8</volume><fpage>e56647</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0056647</pub-id><pub-id pub-id-type="pmid">23437196</pub-id><pub-id pub-id-type="pmcid">3577861</pub-id></element-citation></ref>
<ref id="b47-ijo-47-01-0025"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamakuchi</surname><given-names>M</given-names></name><name><surname>Yagi</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Lowenstein</surname><given-names>CJ</given-names></name></person-group><article-title>MicroRNA-22 regulates hypoxia signaling in colon cancer cells</article-title><source>PLoS One</source><volume>6</volume><fpage>e20291</fpage><year>2011</year><pub-id pub-id-type="doi">10.1371/journal.pone.0020291</pub-id><pub-id pub-id-type="pmid">21629773</pub-id><pub-id pub-id-type="pmcid">3100326</pub-id></element-citation></ref>
<ref id="b48-ijo-47-01-0025"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Si</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth</article-title><source>Cancer Lett</source><volume>333</volume><fpage>159</fpage><lpage>169</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.canlet.2013.01.028</pub-id><pub-id pub-id-type="pmid">23352645</pub-id></element-citation></ref>
<ref id="b49-ijo-47-01-0025"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>ZM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>You</surname><given-names>YP</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>XF</given-names></name><etal/></person-group><article-title>MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1</article-title><source>PLoS One</source><volume>7</volume><fpage>e32709</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0032709</pub-id><pub-id pub-id-type="pmid">22442669</pub-id><pub-id pub-id-type="pmcid">3307714</pub-id></element-citation></ref>
<ref id="b50-ijo-47-01-0025"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name></person-group><article-title>MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis</article-title><source>Nucleic Acids Res</source><volume>40</volume><fpage>761</fpage><lpage>774</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/nar/gkr730</pub-id><pub-id pub-id-type="pmcid">3258133</pub-id></element-citation></ref>
<ref id="b51-ijo-47-01-0025"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>PS</given-names></name><name><surname>Johansson</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>MY</given-names></name><name><surname>Jeng</surname><given-names>YM</given-names></name><name><surname>Yu</surname><given-names>SL</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Chang</surname><given-names>KJ</given-names></name><name><surname>Jee</surname><given-names>SH</given-names></name><etal/></person-group><article-title>MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis</article-title><source>Cancer Res</source><volume>70</volume><fpage>2675</fpage><lpage>2685</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2448</pub-id><pub-id pub-id-type="pmid">20233879</pub-id></element-citation></ref>
<ref id="b52-ijo-47-01-0025"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>G</given-names></name><name><surname>Yan</surname><given-names>HL</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>LQ</given-names></name><name><surname>Zhu</surname><given-names>XT</given-names></name><name><surname>Mei</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>SH</given-names></name></person-group><article-title>c-Myc-mediated repression of miR-15&#x02013;16 in hypoxia is induced by increased HIF-2alpha and promotes tumor angiogenesis and metastasis by upregulating FGF2</article-title><source>Oncogene</source><volume>34</volume><fpage>1393</fpage><lpage>1406</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/onc.2014.82</pub-id></element-citation></ref>
<ref id="b53-ijo-47-01-0025"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>UH</given-names></name><name><surname>Pfent</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Amendt</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wilson-Robles</surname><given-names>H</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name></person-group><article-title>Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells</article-title><source>Mol Cancer Ther</source><volume>11</volume><fpage>108</fpage><lpage>118</lpage><year>2012</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-11-0548</pub-id><pub-id pub-id-type="pmcid">3256275</pub-id></element-citation></ref>
<ref id="b54-ijo-47-01-0025"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>YM</given-names></name><name><surname>Chuang</surname><given-names>CM</given-names></name><name><surname>Chao</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><article-title>MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha</article-title><source>Int J Cancer</source><volume>133</volume><fpage>867</fpage><lpage>878</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/ijc.28086</pub-id><pub-id pub-id-type="pmid">23389731</pub-id></element-citation></ref>
<ref id="b55-ijo-47-01-0025"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>HP</given-names></name><name><surname>Subramanian</surname><given-names>IV</given-names></name><name><surname>Schnettler</surname><given-names>EK</given-names></name><name><surname>Ghosh</surname><given-names>G</given-names></name><name><surname>Rupaimoole</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>C</given-names></name><name><surname>Saluja</surname><given-names>M</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Cristina</surname><given-names>I</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis</article-title><source>Proc Natl Acad Sci USA</source><volume>111</volume><fpage>5331</fpage><lpage>5336</lpage><year>2014</year><pub-id pub-id-type="doi">10.1073/pnas.1317242111</pub-id><pub-id pub-id-type="pmid">24706848</pub-id><pub-id pub-id-type="pmcid">3986124</pub-id></element-citation></ref>
<ref id="b56-ijo-47-01-0025"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pu</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>T</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Q</given-names></name></person-group><article-title>MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha</article-title><source>Oncogene</source><volume>33</volume><fpage>387</fpage><lpage>397</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/onc.2012.574</pub-id></element-citation></ref>
<ref id="b57-ijo-47-01-0025"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><etal/></person-group><article-title>VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1&#x003B1;/VEGF and &#x003B2;-catenin/Tcf-4 signaling</article-title><source>Neuro-oncol</source><volume>14</volume><fpage>1026</fpage><lpage>1036</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/neuonc/nos122</pub-id></element-citation></ref>
<ref id="b58-ijo-47-01-0025"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Cramer</surname><given-names>SD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Sui</surname><given-names>G</given-names></name></person-group><article-title>MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/ HIF-1beta</article-title><source>Mol Cancer</source><volume>9</volume><fpage>108</fpage><year>2010</year><pub-id pub-id-type="doi">10.1186/1476-4598-9-108</pub-id></element-citation></ref>
<ref id="b59-ijo-47-01-0025"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chio</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>JW</given-names></name><name><surname>Cheng</surname><given-names>HA</given-names></name><name><surname>Chiu</surname><given-names>WT</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Hsing</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>RM</given-names></name></person-group><article-title>MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells</article-title><source>Arch Toxicol</source><volume>87</volume><fpage>459</fpage><lpage>468</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s00204-012-0965-5</pub-id></element-citation></ref>
<ref id="b60-ijo-47-01-0025"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group><article-title>Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro</article-title><source>Exp Cell Res</source><volume>318</volume><fpage>944</fpage><lpage>954</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2012.02.010</pub-id><pub-id pub-id-type="pmid">22387901</pub-id></element-citation></ref>
<ref id="b61-ijo-47-01-0025"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>E</given-names></name><name><surname>Zago</surname><given-names>M</given-names></name><name><surname>Sarill</surname><given-names>M</given-names></name><name><surname>Rico de Souza</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>J</given-names></name><name><surname>Hamid</surname><given-names>Q</given-names></name><name><surname>Eidelman</surname><given-names>DH</given-names></name><name><surname>Baglole</surname><given-names>CJ</given-names></name></person-group><article-title>Aryl hydrocarbon receptor-dependent regulation of miR-196a expression controls lung fibroblast apoptosis but not proliferation</article-title><source>Toxicol Appl Pharmacol</source><volume>280</volume><fpage>511</fpage><lpage>525</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.taap.2014.08.023</pub-id><pub-id pub-id-type="pmid">25178717</pub-id></element-citation></ref>
<ref id="b62-ijo-47-01-0025"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aisenberg</surname><given-names>AC</given-names></name><name><surname>Potter</surname><given-names>VR</given-names></name></person-group><article-title>Studies on the Pasteur effect. II Specific mechanisms</article-title><source>J Biol Chem</source><volume>224</volume><fpage>1115</fpage><lpage>1127</lpage><year>1957</year><pub-id pub-id-type="pmid">13405938</pub-id></element-citation></ref>
<ref id="b63-ijo-47-01-0025"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Hemann</surname><given-names>C</given-names></name><name><surname>Mahoney</surname><given-names>CE</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2</article-title><source>Cell Metab</source><volume>10</volume><fpage>273</fpage><lpage>284</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.cmet.2009.08.015</pub-id><pub-id pub-id-type="pmid">19808020</pub-id><pub-id pub-id-type="pmcid">2759401</pub-id></element-citation></ref>
<ref id="b64-ijo-47-01-0025"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname><given-names>RI</given-names></name><name><surname>Blick</surname><given-names>C</given-names></name><name><surname>Ragoussis</surname><given-names>J</given-names></name><name><surname>Schoedel</surname><given-names>J</given-names></name><name><surname>Mole</surname><given-names>DR</given-names></name><name><surname>Young</surname><given-names>AC</given-names></name><name><surname>Selby</surname><given-names>PJ</given-names></name><name><surname>Banks</surname><given-names>RE</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><article-title>miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis</article-title><source>Br J Cancer</source><volume>108</volume><fpage>1133</fpage><lpage>1142</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/bjc.2013.56</pub-id><pub-id pub-id-type="pmid">23449350</pub-id><pub-id pub-id-type="pmcid">3619073</pub-id></element-citation></ref>
<ref id="b65-ijo-47-01-0025"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Favaro</surname><given-names>E</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>McCormick</surname><given-names>R</given-names></name><name><surname>Gee</surname><given-names>H</given-names></name><name><surname>Blancher</surname><given-names>C</given-names></name><name><surname>Crosby</surname><given-names>M</given-names></name><name><surname>Devlin</surname><given-names>C</given-names></name><name><surname>Blick</surname><given-names>C</given-names></name><name><surname>Buffa</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><etal/></person-group><article-title>MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU</article-title><source>PLoS One</source><volume>5</volume><fpage>e10345</fpage><year>2010</year><pub-id pub-id-type="doi">10.1371/journal.pone.0010345</pub-id><pub-id pub-id-type="pmid">20436681</pub-id><pub-id pub-id-type="pmcid">2859946</pub-id></element-citation></ref>
<ref id="b66-ijo-47-01-0025"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Pi</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>M</given-names></name><etal/></person-group><article-title>MiRNA-210 modulates a nickel-induced cellular energy metabolism shift by repressing the iron-sulfur cluster assembly proteins ISCU1/2 in Neuro-2a cells</article-title><source>Cell Death Dis</source><volume>5</volume><fpage>e1090</fpage><year>2014</year><pub-id pub-id-type="doi">10.1038/cddis.2014.60</pub-id><pub-id pub-id-type="pmid">24577088</pub-id><pub-id pub-id-type="pmcid">3944272</pub-id></element-citation></ref>
<ref id="b67-ijo-47-01-0025"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puiss&#x000E9;gur</surname><given-names>MP</given-names></name><name><surname>Mazure</surname><given-names>NM</given-names></name><name><surname>Bertero</surname><given-names>T</given-names></name><name><surname>Pradelli</surname><given-names>L</given-names></name><name><surname>Grosso</surname><given-names>S</given-names></name><name><surname>Robbe-Sermesant</surname><given-names>K</given-names></name><name><surname>Maurin</surname><given-names>T</given-names></name><name><surname>Lebrigand</surname><given-names>K</given-names></name><name><surname>Cardinaud</surname><given-names>B</given-names></name><name><surname>Hofman</surname><given-names>V</given-names></name><etal/></person-group><article-title>miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity</article-title><source>Cell Death Differ</source><volume>18</volume><fpage>465</fpage><lpage>478</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/cdd.2010.119</pub-id><pub-id pub-id-type="pmcid">3131992</pub-id></element-citation></ref>
<ref id="b68-ijo-47-01-0025"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fasanaro</surname><given-names>P</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Lorenzi</surname><given-names>M</given-names></name><name><surname>Pescatori</surname><given-names>M</given-names></name><name><surname>Brioschi</surname><given-names>M</given-names></name><name><surname>Kulshreshtha</surname><given-names>R</given-names></name><name><surname>Banfi</surname><given-names>C</given-names></name><name><surname>Stubbs</surname><given-names>A</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name><etal/></person-group><article-title>An integrated approach for experimental target identification of hypoxia-induced miR-210</article-title><source>J Biol Chem</source><volume>284</volume><fpage>35134</fpage><lpage>35143</lpage><year>2009</year><pub-id pub-id-type="doi">10.1074/jbc.M109.052779</pub-id><pub-id pub-id-type="pmid">19826008</pub-id><pub-id pub-id-type="pmcid">2787374</pub-id></element-citation></ref>
<ref id="b69-ijo-47-01-0025"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Sasayama</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Nakamizo</surname><given-names>S</given-names></name><name><surname>Nishihara</surname><given-names>M</given-names></name><name><surname>Mizukawa</surname><given-names>K</given-names></name><name><surname>Kohta</surname><given-names>M</given-names></name><name><surname>Koyama</surname><given-names>J</given-names></name><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>MicroRNA-183 upregulates HIF-1&#x003B1; by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells</article-title><source>J Neurooncol</source><volume>111</volume><fpage>273</fpage><lpage>283</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s11060-012-1027-9</pub-id></element-citation></ref>
<ref id="b70-ijo-47-01-0025"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>QD</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>ZM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><etal/></person-group><article-title>Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway</article-title><source>PLoS One</source><volume>8</volume><fpage>e64924</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0064924</pub-id><pub-id pub-id-type="pmid">23762265</pub-id><pub-id pub-id-type="pmcid">3677911</pub-id></element-citation></ref>
<ref id="b71-ijo-47-01-0025"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>AhR is negatively regulated by miR-203 in response to TCDD or BaP treatment</article-title><source>Toxicol Res (Camb)</source><volume>2</volume><fpage>142</fpage><lpage>151</lpage><year>2013</year></element-citation></ref>
<ref id="b72-ijo-47-01-0025"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Nakahama</surname><given-names>T</given-names></name><name><surname>Le</surname><given-names>DH</given-names></name><name><surname>Van Son</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>HH</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group><article-title>Aryl hydrocarbon receptor and kynurenine: Recent advances in autoimmune disease research</article-title><source>Front Immunol</source><volume>5</volume><fpage>551</fpage><year>2014</year><pub-id pub-id-type="doi">10.3389/fimmu.2014.00551</pub-id><pub-id pub-id-type="pmid">25400638</pub-id><pub-id pub-id-type="pmcid">4212680</pub-id></element-citation></ref>
<ref id="b73-ijo-47-01-0025"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Flach</surname><given-names>H</given-names></name><name><surname>Onizawa</surname><given-names>M</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>McManus</surname><given-names>MT</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group><article-title>Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210</article-title><source>Nat Immunol</source><volume>15</volume><fpage>393</fpage><lpage>401</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/ni.2846</pub-id><pub-id pub-id-type="pmid">24608041</pub-id><pub-id pub-id-type="pmcid">3996831</pub-id></element-citation></ref>
<ref id="b74-ijo-47-01-0025"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>LY</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><article-title>MicroRNA-17, 20a regulates the proangiogenic function of tumor-associated macrophages via targeting hypoxia-inducible factor 2&#x003B1;</article-title><source>PLoS One</source><volume>8</volume><fpage>e77890</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0077890</pub-id></element-citation></ref>
<ref id="b75-ijo-47-01-0025"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poitz</surname><given-names>DM</given-names></name><name><surname>Augstein</surname><given-names>A</given-names></name><name><surname>Gradehand</surname><given-names>C</given-names></name><name><surname>Ende</surname><given-names>G</given-names></name><name><surname>Schmeisser</surname><given-names>A</given-names></name><name><surname>Strasser</surname><given-names>RH</given-names></name></person-group><article-title>Regulation of the Hif-system by micro-RNA 17 and 20a - role during monocyte-to-macrophage differentiation</article-title><source>Mol Immunol</source><volume>56</volume><fpage>442</fpage><lpage>451</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.molimm.2013.06.014</pub-id><pub-id pub-id-type="pmid">23911400</pub-id></element-citation></ref>
<ref id="b76-ijo-47-01-0025"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csak</surname><given-names>T</given-names></name><name><surname>Bala</surname><given-names>S</given-names></name><name><surname>Lippai</surname><given-names>D</given-names></name><name><surname>Satishchandran</surname><given-names>A</given-names></name><name><surname>Catalano</surname><given-names>D</given-names></name><name><surname>Kodys</surname><given-names>K</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><article-title>microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis</article-title><source>Liver Int</source><volume>35</volume><fpage>532</fpage><lpage>541</lpage><year>2015</year><pub-id pub-id-type="doi">10.1111/liv.12633</pub-id></element-citation></ref>
<ref id="b77-ijo-47-01-0025"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleck</surname><given-names>B</given-names></name><name><surname>Grunig</surname><given-names>G</given-names></name><name><surname>Chiu</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>T</given-names></name><name><surname>Kazeros</surname><given-names>A</given-names></name><name><surname>Reibman</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells</article-title><source>J Immunol</source><volume>190</volume><fpage>3757</fpage><lpage>3763</lpage><year>2013</year><pub-id pub-id-type="doi">10.4049/jimmunol.1201165</pub-id><pub-id pub-id-type="pmid">23455502</pub-id><pub-id pub-id-type="pmcid">3665109</pub-id></element-citation></ref>
<ref id="b78-ijo-47-01-0025"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahama</surname><given-names>T</given-names></name><name><surname>Hanieh</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name><name><surname>Chinen</surname><given-names>I</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Millrine</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Nyati</surname><given-names>KK</given-names></name><name><surname>Dubey</surname><given-names>PK</given-names></name><name><surname>Chowdhury</surname><given-names>K</given-names></name><etal/></person-group><article-title>Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation</article-title><source>Proc Natl Acad Sci USA</source><volume>110</volume><fpage>11964</fpage><lpage>11969</lpage><year>2013</year><pub-id pub-id-type="doi">10.1073/pnas.1311087110</pub-id><pub-id pub-id-type="pmid">23818645</pub-id><pub-id pub-id-type="pmcid">3718186</pub-id></element-citation></ref>
<ref id="b79-ijo-47-01-0025"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance</article-title><source>Exp Cell Res</source><volume>326</volume><fpage>22</fpage><lpage>35</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.yexcr.2014.05.022</pub-id><pub-id pub-id-type="pmid">24930954</pub-id></element-citation></ref>
<ref id="b80-ijo-47-01-0025"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname><given-names>A</given-names></name><name><surname>Storci</surname><given-names>G</given-names></name><name><surname>Guarnieri</surname><given-names>T</given-names></name><name><surname>De Carolis</surname><given-names>S</given-names></name><name><surname>Bertoni</surname><given-names>S</given-names></name><name><surname>Avenia</surname><given-names>N</given-names></name><name><surname>Sanguinetti</surname><given-names>A</given-names></name><name><surname>Sidoni</surname><given-names>A</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Ceccarelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Peroxisome proliferator activated receptor-&#x003B1;/hypoxia inducible factor-1&#x003B1; interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells</article-title><source>PLoS One</source><volume>8</volume><fpage>e54968</fpage><year>2013</year><pub-id pub-id-type="doi">10.1371/journal.pone.0054968</pub-id></element-citation></ref>
<ref id="b81-ijo-47-01-0025"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Bi</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Mo</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1&#x003B1; expression in third-sphere forming breast cancer stem cell-like cells</article-title><source>Cancer Sci</source><volume>103</volume><fpage>1058</fpage><lpage>1064</lpage><year>2012</year><pub-id pub-id-type="doi">10.1111/j.1349-7006.2012.02281.x</pub-id><pub-id pub-id-type="pmid">22435731</pub-id></element-citation></ref>
<ref id="b82-ijo-47-01-0025"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>KL</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>LC</given-names></name><name><surname>Shi</surname><given-names>ZD</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>JX</given-names></name><name><surname>Frank</surname><given-names>TS</given-names></name><etal/></person-group><article-title>MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimo-tuzumab</article-title><source>Mol Cancer</source><volume>13</volume><fpage>63</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1476-4598-13-63</pub-id></element-citation></ref>
<ref id="b83-ijo-47-01-0025"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>B</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Ahmad</surname><given-names>A</given-names></name><name><surname>Azmi</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Sethi</surname><given-names>S</given-names></name><name><surname>Aboukameel</surname><given-names>A</given-names></name><name><surname>Padhye</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment</article-title><source>PLoS One</source><volume>7</volume><fpage>e50165</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0050165</pub-id><pub-id pub-id-type="pmid">23272057</pub-id><pub-id pub-id-type="pmcid">3521759</pub-id></element-citation></ref>
<ref id="b84-ijo-47-01-0025"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>B</given-names></name><name><surname>Ahmad</surname><given-names>A</given-names></name><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Azmi</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Padhye</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>FH</given-names></name></person-group><article-title>Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF</article-title><source>PLoS One</source><volume>7</volume><fpage>e43726</fpage><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0043726</pub-id><pub-id pub-id-type="pmid">22952749</pub-id><pub-id pub-id-type="pmcid">3428287</pub-id></element-citation></ref>
<ref id="b85-ijo-47-01-0025"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babar</surname><given-names>IA</given-names></name><name><surname>Czochor</surname><given-names>J</given-names></name><name><surname>Steinmetz</surname><given-names>A</given-names></name><name><surname>Weidhaas</surname><given-names>JB</given-names></name><name><surname>Glazer</surname><given-names>PM</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><article-title>Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells</article-title><source>Cancer Biol Ther</source><volume>12</volume><fpage>908</fpage><lpage>914</lpage><year>2011</year><pub-id pub-id-type="doi">10.4161/cbt.12.10.17681</pub-id><pub-id pub-id-type="pmid">22027557</pub-id><pub-id pub-id-type="pmcid">3280906</pub-id></element-citation></ref>
<ref id="b86-ijo-47-01-0025"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name></person-group><article-title>Hypoxia-inducible factor-1&#x003B1; inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>661</fpage><lpage>669</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/carcin/bgr320</pub-id><pub-id pub-id-type="pmid">22223846</pub-id></element-citation></ref>
<ref id="b87-ijo-47-01-0025"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>J</given-names></name></person-group><article-title>Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1&#x003B1; in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients</article-title><source>J Gastroenterol Hepatol</source><volume>26</volume><fpage>1630</fpage><lpage>1637</lpage><year>2011</year><pub-id pub-id-type="doi">10.1111/j.1440-1746.2011.06758.x</pub-id><pub-id pub-id-type="pmid">21557766</pub-id></element-citation></ref>
<ref id="b88-ijo-47-01-0025"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>G</given-names></name></person-group><article-title>Activation of aryl hydrocarbon receptor (ahr) by tranilast, an anti-allergy drug, promotes miR-302 expression and cell reprogramming</article-title><source>J Biol Chem</source><volume>288</volume><fpage>22972</fpage><lpage>22984</lpage><year>2013</year><pub-id pub-id-type="doi">10.1074/jbc.M113.475624</pub-id><pub-id pub-id-type="pmid">23821545</pub-id><pub-id pub-id-type="pmcid">3753054</pub-id></element-citation></ref>
<ref id="b89-ijo-47-01-0025"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joo</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Koo</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name></person-group><article-title>miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury</article-title><source>Cell Death Dis</source><volume>4</volume><fpage>e899</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cddis.2013.427</pub-id><pub-id pub-id-type="pmid">24176857</pub-id><pub-id pub-id-type="pmcid">3920955</pub-id></element-citation></ref>
<ref id="b90-ijo-47-01-0025"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejean</surname><given-names>E</given-names></name><name><surname>Renalier</surname><given-names>MH</given-names></name><name><surname>Foisseau</surname><given-names>M</given-names></name><name><surname>Agirre</surname><given-names>X</given-names></name><name><surname>Joseph</surname><given-names>N</given-names></name><name><surname>de Paiva</surname><given-names>GR</given-names></name><name><surname>Al Saati</surname><given-names>T</given-names></name><name><surname>Soulier</surname><given-names>J</given-names></name><name><surname>Desjobert</surname><given-names>C</given-names></name><name><surname>Lamant</surname><given-names>L</given-names></name><etal/></person-group><article-title>Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas</article-title><source>Leukemia</source><volume>25</volume><fpage>1882</fpage><lpage>1890</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/leu.2011.168</pub-id><pub-id pub-id-type="pmid">21778999</pub-id></element-citation></ref>
<ref id="b91-ijo-47-01-0025"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>QY</given-names></name><name><surname>Yin</surname><given-names>QQ</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>CX</given-names></name><name><surname>Duan</surname><given-names>CW</given-names></name><name><surname>Hong</surname><given-names>DL</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>GQ</given-names></name><etal/></person-group><article-title>HIF-1&#x003B1; downregulates miR-17/20a directly targeting p21 and STAT3: A role in myeloid leukemic cell differentiation</article-title><source>Cell Death Differ</source><volume>20</volume><fpage>408</fpage><lpage>418</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/cdd.2012.130</pub-id><pub-id pub-id-type="pmcid">3569981</pub-id></element-citation></ref>
<ref id="b92-ijo-47-01-0025"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertozzi</surname><given-names>D</given-names></name><name><surname>Marinello</surname><given-names>J</given-names></name><name><surname>Manzo</surname><given-names>SG</given-names></name><name><surname>Fornari</surname><given-names>F</given-names></name><name><surname>Gramantieri</surname><given-names>L</given-names></name><name><surname>Capranico</surname><given-names>G</given-names></name></person-group><article-title>The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1&#x003B1; activity by changing miR expression patterns in human cancer cells</article-title><source>Mol Cancer Ther</source><volume>13</volume><fpage>239</fpage><lpage>248</lpage><year>2014</year><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0729</pub-id></element-citation></ref>
<ref id="b93-ijo-47-01-0025"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichner</surname><given-names>Z</given-names></name><name><surname>Mejia-Guerrero</surname><given-names>S</given-names></name><name><surname>Ignacak</surname><given-names>M</given-names></name><name><surname>Krizova</surname><given-names>A</given-names></name><name><surname>Bao</surname><given-names>TT</given-names></name><name><surname>Girgis</surname><given-names>AH</given-names></name><name><surname>Youssef</surname><given-names>YM</given-names></name><name><surname>Yousef</surname><given-names>GM</given-names></name></person-group><article-title>Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways</article-title><source>Am J Pathol</source><volume>180</volume><fpage>1675</fpage><lpage>1687</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.12.030</pub-id><pub-id pub-id-type="pmid">22326755</pub-id></element-citation></ref>
<ref id="b94-ijo-47-01-0025"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>SY</given-names></name><name><surname>Tsai</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name></person-group><article-title>Co-targeting of multiple microRNAs on factor-inhibiting hypoxia-inducible factor (FIH) gene for the pathogenesis of head and neck carcinomas</article-title><source>Head Neck</source><month>Oct</month><day>28</day><year>2014</year><comment>(Epub ahead of print)</comment><pub-id pub-id-type="doi">10.1002/hed.23912</pub-id></element-citation></ref>
<ref id="b95-ijo-47-01-0025"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>LK</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Skuli</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Keith</surname><given-names>B</given-names></name><name><surname>Nathanson</surname><given-names>KL</given-names></name><name><surname>Lal</surname><given-names>P</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name></person-group><article-title>Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2&#x003B1; activity</article-title><source>Cancer Discov</source><volume>4</volume><fpage>53</fpage><lpage>60</lpage><year>2014</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0291</pub-id><pub-id pub-id-type="pmcid">3947282</pub-id></element-citation></ref>
<ref id="b96-ijo-47-01-0025"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CJ</given-names></name><name><surname>Tsai</surname><given-names>MM</given-names></name><name><surname>Hung</surname><given-names>PS</given-names></name><name><surname>Kao</surname><given-names>SY</given-names></name><name><surname>Liu</surname><given-names>TY</given-names></name><name><surname>Wu</surname><given-names>KJ</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><name><surname>Lin</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>KW</given-names></name></person-group><article-title>miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma</article-title><source>Cancer Res</source><volume>70</volume><fpage>1635</fpage><lpage>1644</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2291</pub-id><pub-id pub-id-type="pmid">20145132</pub-id></element-citation></ref>
<ref id="b97-ijo-47-01-0025"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>AK</given-names></name><name><surname>Shanafelt</surname><given-names>TD</given-names></name><name><surname>Cimmino</surname><given-names>A</given-names></name><name><surname>Taccioli</surname><given-names>C</given-names></name><name><surname>Volinia</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>CG</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Chan</surname><given-names>DA</given-names></name><name><surname>Giaccia</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells</article-title><source>Blood</source><volume>113</volume><fpage>5568</fpage><lpage>5574</lpage><year>2009</year><pub-id pub-id-type="doi">10.1182/blood-2008-10-185686</pub-id><pub-id pub-id-type="pmid">19336759</pub-id><pub-id pub-id-type="pmcid">2689054</pub-id></element-citation></ref>
<ref id="b98-ijo-47-01-0025"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells</article-title><source>Cell Prolif</source><volume>47</volume><fpage>587</fpage><lpage>595</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/cpr.12146</pub-id><pub-id pub-id-type="pmid">25348507</pub-id></element-citation></ref>
<ref id="b99-ijo-47-01-0025"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blick</surname><given-names>C</given-names></name><name><surname>Ramachandran</surname><given-names>A</given-names></name><name><surname>Wigfield</surname><given-names>S</given-names></name><name><surname>McCormick</surname><given-names>R</given-names></name><name><surname>Jubb</surname><given-names>A</given-names></name><name><surname>Buffa</surname><given-names>FM</given-names></name><name><surname>Turley</surname><given-names>H</given-names></name><name><surname>Knowles</surname><given-names>MA</given-names></name><name><surname>Cranston</surname><given-names>D</given-names></name><name><surname>Catto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hypoxia regulates FGFR3 expression via HIF-1&#x003B1; and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer</article-title><source>Br J Cancer</source><volume>109</volume><fpage>50</fpage><lpage>59</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/bjc.2013.240</pub-id><pub-id pub-id-type="pmid">23778527</pub-id><pub-id pub-id-type="pmcid">3708569</pub-id></element-citation></ref>
<ref id="b100-ijo-47-01-0025"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/ HIF-1alpha/PKM2 signaling pathway in prostate cancer cells</article-title><source>Tumour Biol</source><volume>35</volume><fpage>8543</fpage><lpage>8550</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s13277-014-2057-z</pub-id><pub-id pub-id-type="pmid">24859886</pub-id></element-citation></ref>
<ref id="b101-ijo-47-01-0025"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umezu</surname><given-names>T</given-names></name><name><surname>Tadokoro</surname><given-names>H</given-names></name><name><surname>Azuma</surname><given-names>K</given-names></name><name><surname>Yoshizawa</surname><given-names>S</given-names></name><name><surname>Ohyashiki</surname><given-names>K</given-names></name><name><surname>Ohyashiki</surname><given-names>JH</given-names></name></person-group><article-title>Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1</article-title><source>Blood</source><volume>124</volume><fpage>3748</fpage><lpage>3757</lpage><year>2014</year><pub-id pub-id-type="doi">10.1182/blood-2014-05-576116</pub-id><pub-id pub-id-type="pmid">25320245</pub-id><pub-id pub-id-type="pmcid">4263983</pub-id></element-citation></ref>
<ref id="b102-ijo-47-01-0025"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>B</given-names></name></person-group><article-title>MiR-138 suppresses expression of hypoxia-inducible factor 1&#x003B1; (HIF-1&#x003B1;) in clear cell renal cell carcinoma 786-O cells</article-title><source>Asian Pac J Cancer Prev</source><volume>12</volume><fpage>1307</fpage><lpage>1311</lpage><year>2011</year></element-citation></ref>
<ref id="b103-ijo-47-01-0025"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>ZP</given-names></name><name><surname>Lu</surname><given-names>NN</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name></person-group><article-title>Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1</article-title><source>Biochim Biophys Acta</source><volume>1829</volume><fpage>239</fpage><lpage>247</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.bbagrm.2012.11.006</pub-id></element-citation></ref>
<ref id="b104-ijo-47-01-0025"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>ZY</given-names></name><name><surname>Bai</surname><given-names>YN</given-names></name><name><surname>Luo</surname><given-names>LX</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>Expression of microRNA-150 targeting vascular endothelial growth factor-A is downregulated under hypoxia during liver regeneration</article-title><source>Mol Med Rep</source><volume>8</volume><fpage>287</fpage><lpage>293</lpage><year>2013</year><pub-id pub-id-type="pmid">23715613</pub-id></element-citation></ref>
<ref id="b105-ijo-47-01-0025"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Terek</surname><given-names>RM</given-names></name></person-group><article-title>MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells</article-title><source>Clin Orthop Relat Res</source><volume>473</volume><fpage>907</fpage><lpage>913</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s11999-014-3842-0</pub-id><pub-id pub-id-type="pmid">25106798</pub-id><pub-id pub-id-type="pmcid">4317450</pub-id></element-citation></ref>
<ref id="b106-ijo-47-01-0025"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Jia</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name></person-group><article-title>The hypoxia-inducible factor-1 regulates the microRNA185 expression through binding to hypoxia response elements sequence 2</article-title><source>Med Oncol</source><volume>30</volume><fpage>756</fpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s12032-013-0756-8</pub-id><pub-id pub-id-type="pmid">24198204</pub-id></element-citation></ref>
<ref id="b107-ijo-47-01-0025"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raimondi</surname><given-names>L</given-names></name><name><surname>Amodio</surname><given-names>N</given-names></name><name><surname>Di Martino</surname><given-names>MT</given-names></name><name><surname>Altomare</surname><given-names>E</given-names></name><name><surname>Leotta</surname><given-names>M</given-names></name><name><surname>Caracciolo</surname><given-names>D</given-names></name><name><surname>Gull&#x000E0;</surname><given-names>A</given-names></name><name><surname>Neri</surname><given-names>A</given-names></name><name><surname>Taverna</surname><given-names>S</given-names></name><name><surname>D&#x02019;Aquila</surname><given-names>P</given-names></name><etal/></person-group><article-title>Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity</article-title><source>Oncotarget</source><volume>5</volume><fpage>3039</fpage><lpage>3054</lpage><year>2014</year><pub-id pub-id-type="pmid">24839982</pub-id><pub-id pub-id-type="pmcid">4102790</pub-id></element-citation></ref>
<ref id="b108-ijo-47-01-0025"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>A</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer</article-title><source>PLoS One</source><volume>9</volume><fpage>e90952</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0090952</pub-id><pub-id pub-id-type="pmid">24632577</pub-id><pub-id pub-id-type="pmcid">3954583</pub-id></element-citation></ref>
<ref id="b109-ijo-47-01-0025"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosby</surname><given-names>ME</given-names></name><name><surname>Kulshreshtha</surname><given-names>R</given-names></name><name><surname>Ivan</surname><given-names>M</given-names></name><name><surname>Glazer</surname><given-names>PM</given-names></name></person-group><article-title>MicroRNA regulation of DNA repair gene expression in hypoxic stress</article-title><source>Cancer Res</source><volume>69</volume><fpage>1221</fpage><lpage>1229</lpage><year>2009</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2516</pub-id><pub-id pub-id-type="pmid">19141645</pub-id><pub-id pub-id-type="pmcid">2997438</pub-id></element-citation></ref>
<ref id="b110-ijo-47-01-0025"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Haider</surname><given-names>HK</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name></person-group><article-title>Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2</article-title><source>J Biol Chem</source><volume>284</volume><fpage>33161</fpage><lpage>33168</lpage><year>2009</year><pub-id pub-id-type="doi">10.1074/jbc.M109.020925</pub-id><pub-id pub-id-type="pmid">19721136</pub-id><pub-id pub-id-type="pmcid">2785158</pub-id></element-citation></ref>
<ref id="b111-ijo-47-01-0025"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>LK</given-names></name><name><surname>Skuli</surname><given-names>N</given-names></name><name><surname>Mucaj</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Zinn</surname><given-names>PO</given-names></name><name><surname>Sathyan</surname><given-names>P</given-names></name><name><surname>Imtiyaz</surname><given-names>HZ</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Davuluri</surname><given-names>RV</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><etal/></person-group><article-title>miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma</article-title><source>Proc Natl Acad Sci USA</source><volume>111</volume><fpage>291</fpage><lpage>296</lpage><year>2014</year><pub-id pub-id-type="doi">10.1073/pnas.1314341111</pub-id><pub-id pub-id-type="pmcid">3890843</pub-id></element-citation></ref>
<ref id="b112-ijo-47-01-0025"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhan</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>MiR-338&#x02013;3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1&#x003B1;</article-title><source>PLoS One</source><volume>9</volume><fpage>e115565</fpage><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0115565</pub-id></element-citation></ref>
<ref id="b113-ijo-47-01-0025"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>EJ</given-names></name><name><surname>Won</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells</article-title><source>J Cancer</source><volume>6</volume><fpage>19</fpage><lpage>28</lpage><year>2015</year><pub-id pub-id-type="doi">10.7150/jca.9591</pub-id><pub-id pub-id-type="pmid">25553085</pub-id><pub-id pub-id-type="pmcid">4278911</pub-id></element-citation></ref>
<ref id="b114-ijo-47-01-0025"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seok</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>YM</given-names></name></person-group><article-title>MicroRNA-382 induced by HIF-1&#x003B1; is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog</article-title><source>Nucleic Acids Res</source><volume>42</volume><fpage>8062</fpage><lpage>8072</lpage><year>2014</year><pub-id pub-id-type="doi">10.1093/nar/gku515</pub-id><pub-id pub-id-type="pmid">24914051</pub-id><pub-id pub-id-type="pmcid">4081109</pub-id></element-citation></ref>
<ref id="b115-ijo-47-01-0025"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Mi</surname><given-names>J</given-names></name></person-group><article-title>Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis</article-title><source>Cell Death Dis</source><volume>5</volume><fpage>e1301</fpage><year>2014</year><pub-id pub-id-type="doi">10.1038/cddis.2014.240</pub-id><pub-id pub-id-type="pmid">24967963</pub-id></element-citation></ref>
<ref id="b116-ijo-47-01-0025"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Mohri</surname><given-names>T</given-names></name><name><surname>Takamiya</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>Y</given-names></name><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group><article-title>Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24</article-title><source>Toxicol Appl Pharmacol</source><volume>260</volume><fpage>222</fpage><lpage>231</lpage><year>2012</year><pub-id pub-id-type="doi">10.1016/j.taap.2012.02.012</pub-id><pub-id pub-id-type="pmid">22387692</pub-id></element-citation></ref>
<ref id="b117-ijo-47-01-0025"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>TC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>PY</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Liao</surname><given-names>YF</given-names></name><name><surname>Hsu</surname><given-names>WM</given-names></name><name><surname>Huang</surname><given-names>HC</given-names></name><name><surname>Juan</surname><given-names>HF</given-names></name></person-group><article-title>Silencing of miR-124 induces neuroblastoma SK-N-SH cell differentiation, cell cycle arrest and apoptosis through promoting AHR</article-title><source>FEBS Lett</source><volume>585</volume><fpage>3582</fpage><lpage>3586</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.febslet.2011.10.025</pub-id><pub-id pub-id-type="pmid">22024478</pub-id></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ijo-47-01-0025" position="float">
<label>Figure 1</label>
<caption>
<p>miRNAs involved in HIF-associated carcinogenic processes. Oncogenic miRNAs (oncomiRs) are normally upregulated and directly target or inhibit tumor suppressors, promoting proliferation, angiogenesis, migration and suppressing apoposis. By contrast, tumor suppressor miRNAs (tsmiRs) are often expressed at low level and attenuate the inhibitory effect on oncogenes.</p></caption>
<graphic xlink:href="IJO-47-01-0025-g00.gif"/></fig>
<table-wrap id="tI-ijo-47-01-0025" position="float">
<label>Table I</label>
<caption>
<p>miRNAs involved in HIF-associated carcinogenic processes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left">miRNAs</th>
<th valign="bottom" align="left">Regulation</th>
<th valign="bottom" align="left">Type</th>
<th valign="bottom" align="left">Targets</th>
<th valign="bottom" align="left">Action</th>
<th valign="bottom" align="left">Refs.</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">miR-15-16</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Colorectal carcinoma</td>
<td valign="top" align="left">FGF2</td>
<td valign="top" align="left">Promotes angiogenesis and metastasis</td>
<td valign="top" align="left">(<xref rid="b52-ijo-47-01-0025" ref-type="bibr">52</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-16</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Multiple tumors</td>
<td valign="top" align="left">VEGF</td>
<td valign="top" align="left">Promotes proliferation and angiogenesis</td>
<td valign="top" align="left">(<xref rid="b90-ijo-47-01-0025" ref-type="bibr">90</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-17</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Tumor-associated macrophages</td>
<td valign="top" align="left">HIF2&#x003B1;</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b74-ijo-47-01-0025" ref-type="bibr">74</xref>,<xref rid="b75-ijo-47-01-0025" ref-type="bibr">75</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-17</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Myeloid leukemic</td>
<td valign="top" align="left">p21 and STAT3</td>
<td valign="top" align="left">Promotes differentiation</td>
<td valign="top" align="left">(<xref rid="b91-ijo-47-01-0025" ref-type="bibr">91</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-17-5p</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Cervical and renal cancer</td>
<td valign="top" align="left">VHL and HIF1&#x003B1;</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b92-ijo-47-01-0025" ref-type="bibr">92</xref>, <xref rid="b93-ijo-47-01-0025" ref-type="bibr">93</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-17-5p</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Breast cancer stem cell</td>
<td valign="top" align="left">PPAR&#x003B1;</td>
<td valign="top" align="left">Regulates inflammation</td>
<td valign="top" align="left">(<xref rid="b80-ijo-47-01-0025" ref-type="bibr">80</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-17-92</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Lung cancer</td>
<td valign="top" align="left">HIF1&#x003B1;</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b34-ijo-47-01-0025" ref-type="bibr">34</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-20a</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Tumor-associated macrophages</td>
<td valign="top" align="left">HIF2&#x003B1;</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b74-ijo-47-01-0025" ref-type="bibr">74</xref>,<xref rid="b75-ijo-47-01-0025" ref-type="bibr">75</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-20a</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Myeloid leukemic</td>
<td valign="top" align="left">p21 and STAT3</td>
<td valign="top" align="left">Promotes differentiation</td>
<td valign="top" align="left">(<xref rid="b91-ijo-47-01-0025" ref-type="bibr">91</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-21</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">HNSCC</td>
<td valign="top" align="left">FIH</td>
<td valign="top" align="left">Promotes proliferation and migration</td>
<td valign="top" align="left">(<xref rid="b94-ijo-47-01-0025" ref-type="bibr">94</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-21</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Pancreatic cancer</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">Regulates proliferation and apoptosis</td>
<td valign="top" align="left">(<xref rid="b29-ijo-47-01-0025" ref-type="bibr">29</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-21</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Prostate cancer</td>
<td valign="top" align="left">PTEN</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b44-ijo-47-01-0025" ref-type="bibr">44</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-22</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Colon cancer</td>
<td valign="top" align="left">HIF1&#x003B1;</td>
<td valign="top" align="left">Regulates growth and invasion</td>
<td valign="top" align="left">(<xref rid="b47-ijo-47-01-0025" ref-type="bibr">47</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-23b</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Gliomas</td>
<td valign="top" align="left">VHL</td>
<td valign="top" align="left">Promotes proliferation and invasion</td>
<td valign="top" align="left">(<xref rid="b57-ijo-47-01-0025" ref-type="bibr">57</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-30a-3p</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Renal cancer</td>
<td valign="top" align="left">HIF2&#x003B1;</td>
<td valign="top" align="left">Promotes growth</td>
<td valign="top" align="left">(<xref rid="b95-ijo-47-01-0025" ref-type="bibr">95</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-30c-2-3p</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Renal cancer</td>
<td valign="top" align="left">HIF2&#x003B1;</td>
<td valign="top" align="left">Promotes growth</td>
<td valign="top" align="left">(<xref rid="b95-ijo-47-01-0025" ref-type="bibr">95</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-31</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">HNSCC</td>
<td valign="top" align="left">FIH</td>
<td valign="top" align="left">Promotes proliferation and migration</td>
<td valign="top" align="left">(<xref rid="b94-ijo-47-01-0025" ref-type="bibr">94</xref>,<xref rid="b96-ijo-47-01-0025" ref-type="bibr">96</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-92-1</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Chronic lymphocytic leukemia</td>
<td valign="top" align="left">VHL</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b97-ijo-47-01-0025" ref-type="bibr">97</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-99a</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Hepatoma and breast cancer</td>
<td valign="top" align="left">mTOR</td>
<td valign="top" align="left">Regulates glycolytic activity</td>
<td valign="top" align="left">(<xref rid="b70-ijo-47-01-0025" ref-type="bibr">70</xref>,<xref rid="b98-ijo-47-01-0025" ref-type="bibr">98</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-100</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Bladder cancer</td>
<td valign="top" align="left">FGFR3</td>
<td valign="top" align="left">Promotes proliferation</td>
<td valign="top" align="left">(<xref rid="b99-ijo-47-01-0025" ref-type="bibr">99</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-101</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Prostate cancer</td>
<td valign="top" align="left">Ezh2</td>
<td valign="top" align="left">Promotes proliferation and invasion</td>
<td valign="top" align="left">(<xref rid="b58-ijo-47-01-0025" ref-type="bibr">58</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-125b</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Ovarian cancer</td>
<td valign="top" align="left">HER2 and HER3</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b46-ijo-47-01-0025" ref-type="bibr">46</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-128</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Glioma and prostate cancer</td>
<td valign="top" align="left">p70S6K1 and RPS6KB1</td>
<td valign="top" align="left">Regulates proliferation, angiogenesis and glycolytic activity</td>
<td valign="top" align="left">(<xref rid="b49-ijo-47-01-0025" ref-type="bibr">49</xref>,<xref rid="b100-ijo-47-01-0025" ref-type="bibr">100</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-130b</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Breast cancer stem cell</td>
<td valign="top" align="left">DDX6</td>
<td valign="top" align="left">Regulates inflammation</td>
<td valign="top" align="left">(<xref rid="b80-ijo-47-01-0025" ref-type="bibr">80</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-135b</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">HNSCC and multiple myeloma</td>
<td valign="top" align="left">FIH</td>
<td valign="top" align="left">Promotes proliferation, migration and angiogenesis</td>
<td valign="top" align="left">(<xref rid="b33-ijo-47-01-0025" ref-type="bibr">33</xref>, <xref rid="b101-ijo-47-01-0025" ref-type="bibr">101</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-138</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Ovarian and renal cancer</td>
<td valign="top" align="left">SOX4 and HIF1&#x003B1;</td>
<td valign="top" align="left">Regulates apoptosis, invasion and migration</td>
<td valign="top" align="left">(<xref rid="b54-ijo-47-01-0025" ref-type="bibr">54</xref>,<xref rid="b102-ijo-47-01-0025" ref-type="bibr">102</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-145</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Neuroblastoma, colon cancer</td>
<td valign="top" align="left">HIF2&#x003B1;, p70S6K1, IRS1 and N-RAS</td>
<td valign="top" align="left">Regulates growth, invasion, metastasis and angiogenesis</td>
<td valign="top" align="left">(<xref rid="b50-ijo-47-01-0025" ref-type="bibr">50</xref>,<xref rid="b56-ijo-47-01-0025" ref-type="bibr">56</xref>,<xref rid="b103-ijo-47-01-0025" ref-type="bibr">103</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-150</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Hepatocyte</td>
<td valign="top" align="left">VEGF-A</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b104-ijo-47-01-0025" ref-type="bibr">104</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-155</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Cervical and renal cancer</td>
<td valign="top" align="left">HIF1&#x003B1;</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b92-ijo-47-01-0025" ref-type="bibr">92</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-155</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Lung cancer</td>
<td valign="top" align="left">FOXO3A</td>
<td valign="top" align="left">Radiosensitizes</td>
<td valign="top" align="left">(<xref rid="b85-ijo-47-01-0025" ref-type="bibr">85</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-181a</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Chondrosarcoma</td>
<td valign="top" align="left">VEGF</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b105-ijo-47-01-0025" ref-type="bibr">105</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-183</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Gliomas</td>
<td valign="top" align="left">IDH2</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b69-ijo-47-01-0025" ref-type="bibr">69</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-184</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">HNSCC</td>
<td valign="top" align="left">FIH</td>
<td valign="top" align="left">Promotes proliferation and migration</td>
<td valign="top" align="left">(<xref rid="b94-ijo-47-01-0025" ref-type="bibr">94</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-185</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Pancreatic cancer</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b106-ijo-47-01-0025" ref-type="bibr">106</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-199a</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Hepatocyte, lung and ovarian cancer</td>
<td valign="top" align="left">HIF1&#x003B1; and HIF2&#x003B1;</td>
<td valign="top" align="left">Regulates proliferation and migration</td>
<td valign="top" align="left">(<xref rid="b30-ijo-47-01-0025" ref-type="bibr">30</xref>,<xref rid="b31-ijo-47-01-0025" ref-type="bibr">31</xref>,<xref rid="b55-ijo-47-01-0025" ref-type="bibr">55</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-199a</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Ovarian cancer</td>
<td valign="top" align="left">HER2 and HER3</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b46-ijo-47-01-0025" ref-type="bibr">46</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR199a-5p</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Lung cancer and multiple myeloma</td>
<td valign="top" align="left">HIF1&#x003B1; and COX2.</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b19-ijo-47-01-0025" ref-type="bibr">19</xref>,<xref rid="b107-ijo-47-01-0025" ref-type="bibr">107</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-199b</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Liver and prostate cancer</td>
<td valign="top" align="left">HIF1&#x003B1;</td>
<td valign="top" align="left">Regulates proliferation and apoptosis</td>
<td valign="top" align="left">(<xref rid="b32-ijo-47-01-0025" ref-type="bibr">32</xref>,<xref rid="b87-ijo-47-01-0025" ref-type="bibr">87</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-210</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Glioma stem cells</td>
<td valign="top" align="left">MNT</td>
<td valign="top" align="left">Inhibits cell cycle progression and viability, promotes differentiation</td>
<td valign="top" align="left">(<xref rid="b79-ijo-47-01-0025" ref-type="bibr">79</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-210</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">T cells</td>
<td valign="top" align="left">HIF1&#x003B1;</td>
<td valign="top" align="left">Promotes differentiation</td>
<td valign="top" align="left">(<xref rid="b73-ijo-47-01-0025" ref-type="bibr">73</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-210</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Neuroblastoma, lung, colon, renal, cervical, ovarian and breast cancer</td>
<td valign="top" align="left">VMP1, ISCU, Bcl-2, COX10, E2F3, RAD52, MNT, PTPN1</td>
<td valign="top" align="left">Regulates metastasis, apoptosis, mitochondrial function, cell cycle, genetic instability; correlates with radioresistance, prognosis</td>
<td valign="top" align="left">(<xref rid="b14-ijo-47-01-0025" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-ijo-47-01-0025" ref-type="bibr">16</xref>,<xref rid="b27-ijo-47-01-0025" ref-type="bibr">27</xref>,<xref rid="b59-ijo-47-01-0025" ref-type="bibr">59</xref>, <xref rid="b64-ijo-47-01-0025" ref-type="bibr">64</xref>,<xref rid="b108-ijo-47-01-0025" ref-type="bibr">108</xref>&#x02013;<xref rid="b110-ijo-47-01-0025" ref-type="bibr">110</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-210-3p</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">GBM</td>
<td valign="top" align="left">HIF3&#x003B1;</td>
<td valign="top" align="left">Hypoxic survival and chemoresistance</td>
<td valign="top" align="left">(<xref rid="b13-ijo-47-01-0025" ref-type="bibr">13</xref>,<xref rid="b22-ijo-47-01-0025" ref-type="bibr">22</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-218</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Mesenchymal tumors</td>
<td valign="top" align="left">RTK</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b111-ijo-47-01-0025" ref-type="bibr">111</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-320</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Oral cancer</td>
<td valign="top" align="left">Neuropilin 1</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b42-ijo-47-01-0025" ref-type="bibr">42</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-338-3p</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Hepatocarcinoma</td>
<td valign="top" align="left">HIF-1&#x003B1;</td>
<td valign="top" align="left">Correlates with chemoresistance and apoptosis</td>
<td valign="top" align="left">(<xref rid="b112-ijo-47-01-0025" ref-type="bibr">112</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-373</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Cervical and breast cancer</td>
<td valign="top" align="left">RAD23B</td>
<td valign="top" align="left">DNA repair and genetic instability</td>
<td valign="top" align="left">(<xref rid="b109-ijo-47-01-0025" ref-type="bibr">109</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-374b</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Prostate cancer</td>
<td valign="top" align="left">HIF-1&#x003B1; and VEGF</td>
<td valign="top" align="left">Inhibits angiogenesis</td>
<td valign="top" align="left">(<xref rid="b113-ijo-47-01-0025" ref-type="bibr">113</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-382</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Gastric cancer</td>
<td valign="top" align="left">PTEN</td>
<td valign="top" align="left">Promotes angiogenesis</td>
<td valign="top" align="left">(<xref rid="b114-ijo-47-01-0025" ref-type="bibr">114</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-424</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Colon cancer and melanoma</td>
<td valign="top" align="left">PDCD4</td>
<td valign="top" align="left">Inhibits apoptosis</td>
<td valign="top" align="left">(<xref rid="b115-ijo-47-01-0025" ref-type="bibr">115</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-485-5p</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Soft tissue sarcoma</td>
<td valign="top" align="left">HIF-3&#x003B1;</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b22-ijo-47-01-0025" ref-type="bibr">22</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-503</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Hepatoma</td>
<td valign="top" align="left">FGF2 and VEGFA</td>
<td valign="top" align="left">Regulates angiogenesis</td>
<td valign="top" align="left">(<xref rid="b48-ijo-47-01-0025" ref-type="bibr">48</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-519c</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Renal cancer</td>
<td valign="top" align="left">HIF-1&#x003B1;</td>
<td valign="top" align="left">Inhibits angiogenesis</td>
<td valign="top" align="left">(<xref rid="b51-ijo-47-01-0025" ref-type="bibr">51</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-566</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Glioblastoma</td>
<td valign="top" align="left">VHL</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b82-ijo-47-01-0025" ref-type="bibr">82</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-3195</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Prostate cancer</td>
<td valign="top" align="left">HIF-1&#x003B1; and VEGF</td>
<td valign="top" align="left">Inhibits angiogenesis</td>
<td valign="top" align="left">(<xref rid="b113-ijo-47-01-0025" ref-type="bibr">113</xref>)</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-ijo-47-01-0025">
<p>IRS1, insulin receptor substrate-1; VMP1, vacuole membrane protein 1; PTEN, phosphatase and tensin homolog; RPS6KB1, ribosomal protein S6 kinase 1; IDH2, isocitrate dehydrogenase 2; RTK, receptor tyrosine kinase; ND, not determined.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="tII-ijo-47-01-0025" position="float">
<label>Table II</label>
<caption>
<p>miRNAs involved in AHRs associated carcinogenic processes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="bottom" align="left">miRNAs</th>
<th valign="bottom" align="center">Regulation</th>
<th valign="bottom" align="center">Type</th>
<th valign="bottom" align="center">Targets</th>
<th valign="bottom" align="center">action</th>
<th valign="bottom" align="center">Refs.</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">miR-24</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Hepatocellular carcinoma</td>
<td valign="top" align="left">ARNT</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b116-ijo-47-01-0025" ref-type="bibr">116</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-25</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Multiple myeloma</td>
<td valign="top" align="left">p53</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b24-ijo-47-01-0025" ref-type="bibr">24</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-107</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Pituitary adenomas</td>
<td valign="top" align="left">AIP</td>
<td valign="top" align="left">Inhibits proliferation</td>
<td valign="top" align="left">(<xref rid="b35-ijo-47-01-0025" ref-type="bibr">35</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-124</td>
<td valign="top" align="left">Down</td>
<td valign="top" align="left">Neuroblastoma</td>
<td valign="top" align="left">AHR</td>
<td valign="top" align="left">Promotes differentiation, cell cycle arrest and apoptosis</td>
<td valign="top" align="left">(<xref rid="b117-ijo-47-01-0025" ref-type="bibr">117</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-125b</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Renal cancer</td>
<td valign="top" align="left">AhRR</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b89-ijo-47-01-0025" ref-type="bibr">89</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-196a</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Hepatocellular carcinoma</td>
<td valign="top" align="left">ARNT</td>
<td valign="top" align="left">Promotes proliferation</td>
<td valign="top" align="left">(<xref rid="b61-ijo-47-01-0025" ref-type="bibr">61</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-221</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Breast cancer</td>
<td valign="top" align="left">SOX4</td>
<td valign="top" align="left">Inhibits metastasis</td>
<td valign="top" align="left">(<xref rid="b37-ijo-47-01-0025" ref-type="bibr">37</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-335</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Bronchial epithelial cells</td>
<td valign="top" align="left">AHR</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">(<xref rid="b53-ijo-47-01-0025" ref-type="bibr">53</xref>)</td></tr>
<tr>
<td valign="top" align="left">miR-375</td>
<td valign="top" align="left">Up</td>
<td valign="top" align="left">Fibroblast</td>
<td valign="top" align="left">ND</td>
<td valign="top" align="left">Inhibits apoptosis</td>
<td valign="top" align="left">(<xref rid="b77-ijo-47-01-0025" ref-type="bibr">77</xref>)</td></tr></tbody></table></table-wrap></floats-group></article>
